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 Abdominal aortic aneurysm (AAA) is a dilatation of the abdominal aorta, characterized 
by degenerative changes and expansion of the entire vessel wall. AAA is the most common of a 
spectrum of aortic diseases, which includes aneurysms, pseudoaneurysms and dissections. 
Aneurysmal disease can occur at several sites in the aorta, resulting from variety of etiologies 
(Figure 1), but the most common are infrarenal AAAs with uncertain etiology. Aneurysms 
develop after an initial insult to the vessel wall, followed by slow, progressive expansion. As an 
aneurysm grows, the wall will weaken further and can eventually rupture, often resulting in 
massive bleeding and rapid death.  
 The disease burden of AAA is significant, particularly in the elderly population. Its 
prevalence is approximately 2% in the general population and is as high as 10% in older men1-3. 
According to mortality statistics from the Centers for Disease Control, AAA accounts for 
approximately 15,000 deaths per year, making it the 17th leading cause of death4. This may, 
however, underestimate the true disease burden. Since AAA is usually asymptomatic until 
sudden rupture, death from undiagnosed aneurysms may be attributed to comorbid conditions, 
such as coronary artery disease (CAD). Despite the grim statistics, aneurysms are easily 
treatable when diagnosed early. The only currently available therapy, elective repair, either 
surgical or endovascular, is highly effective, with a mortality of less than 5% as compared with 
up to a 90% mortality associated with rupture5,6. In order to provide timely repair, early detection 
is necessary. Yet, since universal screening has been deemed cost-prohibitive7, many 
asymptomatic aneurysms are found incidentally during imaging studies for unrelated conditions. 
Additionally, due to advanced age or comorbid disease, some patients may not be appropriate 
candidates for surgery. Ideally, better screening strategies could identify those most at risk of 
developing an aneurysm and they could be treated pharmacologically to slow or prevent 
aneurysm growth. 
 As a multifactorial disease, AAA formation is contributed to by environmental and 
genetic risk factors. Age increases susceptibility to AAA formation, as aneurysms rarely occur 
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before the age of 50 and increase in prevalence with age2,3,8-11. Susceptibility to AAA also differs 
by sex, with men approximately 5 times more likely to develop an aneurysm, as well as by race, 
with Caucasians being at higher risk of developing an aneurysm8-14. Several modifiable risk 
factors are associated with AAA including smoking, physical inactivity, atherosclerosis, 
hypertension, and hyperlipidemia12. Smoking is particularly important, increasing the risk of 
developing an AAA approximately 5-fold 8,10,12,15. Surprisingly, diabetes mellitus, which is a risk 
factor for other vascular diseases, has a protective effect in AAA11,12. Genetic differences also 
contribute to AAA risk, with approximately 13% of AAA patients having a positive family history 
of the disease16. Population-based studies show that having a family history of AAA 
approximately doubles the risk of developing an aneurysm12,17.  
 Although there are well-described risk factors and processes known to contribute to AAA 
etiology and pathogenesis, much concerning the precise mechanisms involved in initiation, 
growth and rupture of AAAs is still poorly understood. AAA is invariably associated with the 
presence of atherosclerosis, an association that often leads AAA to be described as a direct 
sequela of atherosclerosis18.  Atherosclerotic changes with age are nearly universal19, however, 
whereas AAA only occurs in a subset of individuals, suggesting that there are additional factors 
responsible for AAA formation20. Age-related changes in the aorta are in most cases necessary 
but not sufficient for AAA formation, since most elderly individuals do not develop an aneurysm. 
Smoking greatly increases the risk of developing an AAA, but its mechanism of action has not 
been elucidated. Factors specific to the abdominal aorta may also contribute; AAA are several 
times more prevalent than thoracic aortic aneurysms and dissections (TAAD) and have different 
risk factors and pathogenesis21-23. 
 Most of our understanding of the mechanisms contributing to AAA is primarily confined 
to the later stages of the disease, in large part due to the availability of aneurysm tissue from 
elective repairs. Late-stage AAA tissue exhibits inflammatory and degenerative changes to the 
entire vascular wall. The extracellular matrix (ECM), consisting of primarily of the structural 
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proteins elastin and collagen, is progressively degraded and there is loss of smooth muscle cell 
(SMC) density24. Growing evidence indicates a central role for the immune system; infiltrates 
containing lymphocytes, macrophages, mast cells, and neutrophils throughout the vessel wall, 
especially adventitia, are a distinguishing feature of AAA. These infiltrating cells contribute to 
weakening of the aortic wall through several mechanisms, including release of ECM degrading 
proteolytic enzymes such as matrix metallopeptidases (MMPs) and cathepsins, induction of 
SMC apoptosis and production of reactive oxygen species. Unfortunately, even with an 
improved understanding of AAA pathogenesis, efforts to slow or reverse AAA growth with 
pharmacotherapeutics, including beta-blockers25, statins26-29, and antibiotics30-34 have given 
mixed results, and no therapies have yet been validated in large clinical trials. In order to 
develop improved therapeutics, a better understanding of the specific genes and pathways 
involved in AAA pathogenesis will be necessary. 
 One strategy to studying the molecular determinants of AAA pathogenesis is through the 
identification of AAA risk loci. This strategy not only offers the possibility to find genes or 
pathways relevant to AAA formation, but also to develop genetic screening to identify those at 
the most risk of developing the disease. Identification of risk loci is done using genetic linkage or 
association methods. Linkage analysis, which examines allele sharing between related 
individuals, is a powerful method of identifying loci that exert a strong genetic effect within 
families35. Two published linkage analyses of AAA-affected relative pairs have identified regions 
on chromosomes 19q13 and 4q31 as genetic risk loci36,37. The major disadvantage to these 
studies, however, is relatively poor resolution, since each AAA loci contains hundreds of genes. 
In contrast, genetic association studies usually identify one or two genes by examining the 
association between the genotype at a polymorphic locus, usually a single nucleotide 
polymorphism (SNP) and the phenotype of interest. Potential drawbacks to association studies, 
however, are the need for large sample sizes and the potential for spurious association resulting 
from the genetic structure of the population under study. Many genetic association studies of 
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AAA have been underpowered with small sample sizes, but significant associations with 
variants in genes such as AGTR1 and ANRIL have been identified using large, diverse study 
populations38,39. An additional challenge for genetic association studies is SNP selection. 
Genome-wide association studies (GWAS) offer the potential for comprehensive genetic 
coverage but may lose significance after correction for multiple testing. In contrast, candidate 
gene association studies test fewer variants but increase the likelihood of missing relevant 
variants. Combining methodologies is one potential way to identify specific genes with strong 
genetic effects. For instance, testing positional candidate genes within linkage loci by 
association methods has been used successfully to identify risk genes in several diseases40-43. 
Additionally, positional candidates can be further prioritized using gene expression data from 
disease tissue and knowledge of the gene function44. 
 An alternative strategy for studying the molecular genetics of a complex disease such as 
AAA is gene expression profiling. Comparison of gene expression between AAA tissue and 
normal abdominal aorta can identify upregulated or downregulated genes. Quantitative 
polymerase chain reaction (PCR) allows for the study of the expression of one or a small 
number of genes simultaneously and is useful for studying genes with good evidence for 
potential disease involvement. Studies of gene expression in AAA have utilized PCR-based 
methods in identifying the contribution of MMPs, cathepsins and cytokines to aneurysm 
pathogenesis. In contrast, several commercially available microarray platforms allow for 
examination of whole genome expression profiles and identification of transcripts not previously 
identified in disease pathogenesis. By utilizing gene annotation databases such as gene 
ontology (GO)45 or the Kyoto Encyclopedia of Genes and Genomes (KEGG)46, significantly 
upregulated pathways or categories of genes can be identified. Three whole genome microarray 
analyses of AAA have been published, which compared gene expression profiles between 
aneurysmal and control abdominal aorta, ruptured and unruptured segments of AAA tissue and 
blood from AAA patients and controls, respectively47-49. The former, published by our laboratory, 
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identified novel expression of genes such as the gene runt related transcription factor 3 
(RUNX3) and demonstrated upregulation of leukocyte signaling pathways48. One limitation of all 
gene expression studies, however, is that transcript levels do not always correlate with protein 
levels. Therefore, confirmation of protein expression with methods such as immunoblotting or 
immunohistochemistry is necessary. 
 Another limitation of most studies examining gene expression from AAA tissue is that 
they were not able to specifically address AAA formation since they relied on tissue from late-
stage disease. Since it is currently not possible to identify and obtain tissue from aneurysms 
very early in their development, alternative strategies must be devised to address this question. 
Identification of AAA risk loci has been proposed above as one such strategy. Additional 
methods are necessary, however, since these methods may only identify a small number of 
genes. Furthermore, aneurysms with a familial component may be sufficiently different from 
sporadic cases in etiology. Another strategy is to identify those genes that exhibit expression 
unique to the abdominal aorta. As previously mentioned, aneurysms have a propensity to form 
inferior to the renal arteries in the abdominal aorta. Several characteristics distinguish the 
abdominal aorta from the thoracic aorta, including ECM protein composition50, SMC lineage51 
and blood flow dynamics52. Therefore, it is likely that these differences are reflected at the level 
of gene expression. 
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1.1 Specific Aims 
 Over the past 20 years, our knowledge of risk factors for AAA and the mechanisms 
involved in aneurysm growth has grown dramatically. Despite these advancements, there is still 
clear need for further improvements. Many cases of AAA go undetected and there have been 
no effective pharmacotherapeutics developed for the disease. To address these problems, a 
better understanding of the molecular mechanisms responsible for aneurysm formation is 
necessary. The research presented here examines these mechanisms from two perspectives.  
Specifically, the study had the following aims:  
1. Determine whether AAA risk alleles are present in CD22, PEPD, CEBPG or other functional 
candidate genes within the AAA linkage intervals on chromosomes 19q13 and 4q31. 
a. A genetic association study was carried out by genotyping SNPs in and around ten 
functional candidate genes. 
b. Exon sequencing was performed on three genes with evidence of nominal 
association, CD22, PEPD, and CEBPG, in order to identify additional variants for further 
study. 
2. Study spatial gene expression in the aorta to identify genes of potential relevance to the 
localized nature to AAA. 
a. A microarray screening study of entire baboon aortas was undertaken to identify 
genes with regional expression in the aorta 
b. Confirmation of protein expression was conducted for one gene of interest, HOXA4, 
using western blots and immunohistochemical staining of human aortic tissue and in 
vitro analysis of low passage aortic ECs and SMCs. 
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CHAPTER 2 – BACKGROUND AND SIGNIFICANCE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of this chapter were reproduced with permission from: 
Lillvis J, Lenk GM, Kuivaniemi H. Genetics of Abdominal Aortic Aneurysms. In: Aortic 
Aneurysms: Pathogenesis and Treatment, Humana Press Inc., Totowa, NJ 2008. 
Nischan J, Lenk GM, Boddy AM, Lillvis JH, Tromp G, Kuivaniemi H. Abdominal aortic 
aneurysms- a complex genetic disease. In: Aneurysms: Risks, Formation and Treatment, Nova 
Science Publishers, Inc., Hauppauge, NY 2009. 
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2.1 Pathology and Natural History of Abdominal Aortic Aneurysms 
 Aneurysms form when changes result in weakening and expansion of the entire vessel 
wall. True aneurysms should be distinguished from pseudoaneurysms and dissecting 
aneurysms, which occur when a tear in an artery wall causes a hematoma to form either outside 
or within the wall of the vessel, but do not involve all three histological layers of a vessel. The 
aorta is the most common site of aneurysm formation, but they can also form at other vascular 
sites including the Circle of Willis, popliteal arteries and coronary arteries. In the aorta, AAA are 
six times more common than thoracic aortic aneurysms (TAA), and approximately 80% of AAA 
occur between the renal arteries and iliac bifurcation. The etiology of most AAA is not known 
and they are therefore referred to as nonspecific aneurysms; nonspecific AAAs are also 
commonly known as atherosclerotic aneurysms due to the presence of atherosclerotic changes. 
Less common are inflammatory AAA, which are characterized by a thickened wall and 
retroperitoneal fibrosis53, as are mycotic AAAs, which form as a result of an infection of the 
aortic wall, usually from Staphylococcus or Salmonella species54. 
 On gross examination (Figure 2), aneurysms exhibit varying size and shape18. Large 
aneurysms can exceed 10 cm in diameter and may reach from the renal arteries to the iliac 
bifurcation. A significant minority of cases may also have iliac artery aneurysms. Aneurysms can 
be fusiform or saccular in shape. The walls of an AAA will typically show signs of thinning and 
the luminal surface will have gross evidence of atherosclerotic lesions. Thrombus formation can 
also be observed in the dilated region of the aneurysm. 
 In histological sections, several distinct features are observed in AAA. As an elastic 
artery, the aorta has three histological layers, the tunicas intima, media and adventitia, with the 
medial layer composed of elastic lamellae consisting of alternating layers of SMCs and elastin 
fibers. As AAA progresses, there is a characteristic destruction of the elastic lamellae, with 
elastic fiber fragmentation observed by Verhoeff-van Gieson staining. Loss of medial SMCs to 
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apoptosis is also observed24. In the adventitial layer, there are extensive inflammatory infiltrates 
as well as a loss of collagen in advanced cases of AAA55. Inflammation may also be observed in 
the intima and consists of atherosclerosis-associated macrophages and T-cells. In contrast, 
AAA-associated infiltrates in the outer medial and adventitial layers consist primarily of 
lymphocytes but can include other leukocyte cell types56-60. These immune infiltrates are 
increasingly recognized as critical to aneurysm formation and will be discussed in detail below. 
 The natural history of an AAA is characterized by slow progressive growth. By the time 
the aorta has expanded enough to be classified as aneurysmal, it will almost invariably continue 
to increase in size until it ruptures or the patient dies of another cause. This growth proceeds 
slowly; aneurysms grow only a few millimeters annually, although the rate of growth will 
increase as the aneurysm diameter increases61,62.  
 The clinical presentation of an AAA varies significantly and depends on if and where it 
has ruptured. Unruptured aneurysms are typically asymptomatic, although symptoms including 
pulsations, abdominal or back pain, nausea, or symptoms of claudication or embolism may 
develop from the aneurysm pressing on surrounding structures63. A majority of aneurysms 
rupture into the retroperitoneal space, often presenting as the triad of back pain, hypotension 
and a pulsatile mass64. Most of the remaining ruptures are directly into the peritoneal cavity, 
which can quickly result in hypovolemic shock and death63. Aneurysms may also rarely rupture 
into the vena cava or duodenum via fistula formation65. 
2.2 Epidemiology and Risk Factors of Abdominal Aortic Aneurysms 
 AAA is a significant disease of aging with approximately 5-10% of individuals over the 
age of 65 harboring an aneurysm. Increasing age contributes to AAA risk, as demonstrated by 
both population screening and autopsy series2,8,10-12. Aneurysms are not usually detectable in 
individuals under the age of 5015 unless associated with other diseases like the Marfan 
Syndrome66, although there are rare exceptions67.  
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 Other demographic factors also modify the risk of developing an AAA. Male sex is 
strongly associated with AAA risk; the prevalence of aneurysms in men is 4-6 times higher than 
in women8-10,12-14. In the Aneurysm Detection and Management (ADAM) trial, a screening study 
of approximately 125,000 Veterans Administration patients, females had approximately half of 
the risk of developing a small aneurysm, defined as a diameter between 3 and 3.9 cm, than 
males (OR 0.47, 95% CI 0.32-0.69) and one fifth the risk of developing an aneurysm 4.0 cm or 
greater in diameter (OR 0.18, 95% CI 0.07-0.48)12. Caucasian race is also associated with AAA 
risk. A comparison of blacks and Caucasians from the same geographic area showed fewer 
aneurysms detected by screening and autopsy68. In a different study, fewer blacks presented for 
treatment for aortic aneurysms and with a lower percentage of cases that were classified as 
nonspecific AAA69. In the ADAM (ADAM) trial, this translated to 40-50% risk reduction in blacks 
for developing both small (OR 0.62; 95% CI 0.53-0.73) and large aneurysms (OR 0.53, 95% CI 
0.40-0.69)12. 
 There are several modifiable risk factors for AAA, with smoking having the strongest 
effect. A history of tobacco use increases the odds of developing an aneurysm by 3- to 5-
fold8,10,12,15. Recent smoking history appears to be most important, as current smokers are at 
increased risk relative to ex-smokers10. Smoking is also dose-dependent, as increased 
cigarettes smoked per day, both in current and ex-smokers, as well as increased number of 
years spent smoking are also associated with higher risks of developing an aneurysm10. 
 Many individuals with AAA will also have comorbid cardiovascular disease. As noted 
above, atherosclerotic changes are seen on the luminal surface of most aneurysms. 
Atherosclerosis, as well as hypertension, coronary artery disease and hypercholesterolemia, 
have been identified in 30-60% of AAA patients12. On the other hand, atherosclerosis, 
hypertension and hypercholesterolemia are seen in much younger patients and are far more 
prevalent than AAA. Furthermore, relative to other risk factors, the contributions of these 
diseases to AAA risk are modest, with odds ratios ranging 1.15 to 1.66 in the ADAM trial. This 
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suggests that while these diseases may contribute to vascular injury leading to AAA formation, 
their role is not specific. Interestingly, and for reasons not fully understood, type II diabetes 
mellitus acts as a protective factor for AAA development11,12. This effect and many of the other 
risk factors have been independently confirmed in a separate population11. 
 A history of physical inactivity has also been associated with AAA formation15. Exercise 
is well-known to reduce the risk and improve the sequelae of cardiovascular diseases, including 
hypertension, diabetes mellitus, and CAD70. With respect to aneurysms, exercise training can 
decrease vascular wall stiffness71 and compared to matched controls, patients with AAA exhibit 
an increase in arterial stiffness72. 
2.3 The Genetics of Abdominal Aortic Aneurysms 
 Evidence strongly suggests that genetic risk factors also contribute significantly to AAA 
risk. Aneurysms of the abdominal aorta may occur as a result of well-described genetic 
disorders resulting in blood vessel weakness such as the Marfan syndrome and the Ehlers-
Danlos syndrome66,73. However, these do not account for a significant percentage of AAA cases 
and AAAs are rare compared with TAA in these patients. Clustering of AAA within families with 
no detectable genetic disorder was first observed in a case report describing three brothers with 
the disease74. Since then, several case series and ultrasound screening studies have supported 
this observation. Approximately 10-15% of AAA patients report a positive family history (Table 
1), although this percentage varies considerably by the population under study, as well as 
patient characteristics (i.e. ruptured vs. unruptured, cases detected by screening vs. presenting 
for treatment). Screening studies of siblings of AAA patients show similar results, with 230 of 
1,723 siblings harboring an AAA (Table 2). Consistent with the increased risk of AAA in men, 
brothers of AAA patients are at particular risk with an AAA present in almost 20%.  
 Quantitatively, family history is an important risk factor at the population level. In the 
ADAM trial, only smoking history and gender had stronger effects on AAA risk than family 
history (OR 1.93, 95% CI 1.71-2.18 for small aneurysms; OR 1.94, 95% CI 1.63-2.32 for large 
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aneurysms)12. A study by Larsson, et al. utilized national registries of medical history, cause of 
death, and family relationships in Sweden to examine AAA family history at the population 
level17. Out of 3183 AAA cases identified through either the medical record or cause of death 
registries, 8.4% were identified as having a family relationship with another AAA case as 
compared with 4.6% of 15,943 population controls. This translates to similar risk associated with 
family history as observed in the ADAM trial (OR 1.9; 95% CI 1.6-2.2)17. Furthermore, higher 
risk was observed with additional affected family members, which is consistent with our 
knowledge of genetic disorders.  
 Twin-based studies are also useful in demonstrating that a disease has a genetic 
component. These studies rely on the observation that sharing of environmental exposures 
does not differ between monozygotic and dizygotic twins but the number of shared alleles does. 
If a trait has a genetic basis, the odds of a monozygotic twin of an AAA patient having the 
disease would be higher than dizygotic twin. A study of 265 twins with AAA in Sweden 
demonstrated that the odds ratio for a monozygotic twin of AAA patient developing the disease 
was 71.1 (95% CI 27.5-183.4) compared to 7.6 (95% CI 3.0-19.2) for a dizygotic twin75. Seventy 
percent of the total trait variance was calculated to be from genetic factors, with only 30% from 
environmental factors, strongly supporting the concept that genetic factors contribute to AAA 
risk.  
 AAA exhibits additional characteristics consistent with being a genetic disease.  
Majumder, et al. and Verloes, et al. studied 91 and 313 families of AAA patients, respectively, 
using a statistical approach known as segregation analysis to demonstrate that AAA is a 
heritable trait76,77. Segregation analysis compares the observed pattern of disease in a set of 
pedigrees versus the patterns expected from different genetic models and determines the model 
that most likely explains the observed data. Both of these studies concluded that a major gene 
effect was responsible for AAA risk within families, but disagreed on the mode of inheritance, 
one identifying a recessive model and the other a dominant model76,77. One possible 
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explanation for this discrepancy is that different genes may be responsible for increased AAA 
risk in different families. In addition to the formal statistical analyses supporting the genetic 
nature of AAA, several collections of AAA families have been reported, the largest one 
describing 233 families with multiple affecteds78. 
 AAA also demonstrates characteristics of being a multifactorial genetic disease with 
respect to gender. One feature of multifactorial diseases is gender-discrepancy in prevalence, a 
phenomenon that is well documented in diseases such as pyloric stenosis, many congenital 
heart defects, neural tube defects and cleft lip79. As noted above, males are at increased risk of 
developing an aneurysm. However, when females do present with an aneurysm, it is 
presumably due to having a greater genetic or environmental liability and therefore should 
represent the more severe end of the spectrum of disease80. This is supported by the fact that 
females have an increased aneurysm growth rate81, have increased operative mortality for both 
intact and ruptured AAAs compared to males82,83, and there is increased inflammation in the 
walls of resected aneurysms from female patients84. Additionally, if this liability is genetic, one 
would expect to see a higher prevalence among females inheriting the mutations. In one study 
of 542 AAA patients, the 82 (15.1%) patients who had a positive family history were compared 
to the 460 sporadic cases85. When examined for gender distribution, the sporadic cases 
presented with an 86%:14% ratio of males to females, whereas 35% of the familial cases were 
female, despite no differences in smoking, hypertension, or coronary artery disease. An 
investigation of rupture rates of the patients with a positive family history, as well as their first-
degree relatives, found that 22/73 (30.1%) aneurysms in females ruptured as compared to 
23/136 (16.9%) in males85. Finally, it was also found that the males with a family history were 
younger than the males with sporadic aneurysms, another characteristic consistent with genetic 
diseases85. Similar results were reported in a different study of 300 AAA patients that showed a 
higher rate of rupture among familial cases of AAA86. 
2.4 Clinical Diagnosis and Management 
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 Diagnosis of an AAA is made by imaging studies in either symptomatic individuals or 
incidentally during a test for an unrelated condition. AAA is typically defined as an absolute 
infrarenal diameter greater than 3 cm, although alternative diagnostic criteria may be used, such 
as an infrarenal to suprarenal diameter ratio greater than 1.2. Ultrasound (US) is the modality of 
choice for detection and monitoring, as it is inexpensive, has high sensitivity and specificity and 
does not require exposure to ionizing radiation. US is subject to problems in overweight or non-
fasting individuals, potentially missing the presence of an AAA87. Computed tomography (CT) 
and magnetic resonance imaging (MRI) are typically not used as screening tools, but offer 
better resolution than US and provide a more complete picture of aneurysm geometry and 
location. 
 Therapy for AAA is currently limited to surgical repair. Two major surgical approaches 
are utilized, open surgical grafting and endovascular stent-grafting88. Each of these approaches 
has advantages and there is currently ongoing debate about their appropriate uses. 
Endovascular repair is minimally invasive and has slightly lower mortality at 1 month post-
procedure, but mortality at 2 years is comparable89,90. Endovascular repair is more expensive, 
suggesting that open repair may be more suitable91. It is possible that endovascular repair may 
be appropriate for some individuals unfit for open repair, but a comparison of endovascular 
repair versus no intervention in 400 such patients showed higher costs associated with 
treatment and no benefits in all-cause mortality92. It has also been suggested that endovascular 
repair may be appropriate for repair of small aneurysms93-95, but the recent results of the 
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL) trial, a 
randomized trial comparing endovascular repair to ultrasound monitoring in 728 patients with 
AAAs between four and five centimeters in diameter demonstrated neither benefit nor harm 
from early repair96. 
 Optimal management of AAA relies on diagnosis and therapy prior to aneurysm rupture. 
Approximately 50% of individuals with a ruptured AAA die prior to reaching the emergency room 
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and a significant proportion of the other 50% do not survive the repair operation6. In 
comparison, elective repair has a mortality of less than 5%5. Since most unruptured AAAs are 
asymptomatic, however, there has been interest in developing screening protocols for AAA. 
Similar to colonoscopies and mammograms for detection of colon and breast cancers, 
respectively, population screening of elderly individuals with abdominal ultrasound has been 
proposed for AAA. Large trials screening for AAA suggest that it may be cost-effective in men 
65-75, but would likely not be for whole population screening7,97-100. Rather, currently proposed 
screening guidelines are targeted, incorporating additional risk factors, including smoking and 
family history7,101-104. Going forward, one possibility is that a better understanding of AAA genetic 
risk variants would help to identify those most at risk of developing an aneurysm. 
 Even with a diagnosed AAA, appropriate timing of surgical repair is problematic. Despite 
low mortality, elective repair is not risk-free. Several factors are associated with an increased 
risk of rupture, including smoking and female sex, but the most clinically useful parameter is 
aneurysm size61. Population trials have established an aneurysm diameter of 5.5 cm as having 
a risk of rupture greater than the risk of repair61. Not all of the factors involved in aneurysm 
rupture are known and rupture of small aneurysms is possible. Imaging technologies show 
some potential to identify high-risk aneurysms105, but the cost associated with these tests may 
be high. 
 Ideally, aneurysm rupture or even formation could be prevented using medical therapies 
aimed at slowing or reversing aneurysm growth. Given an annual average growth rate of 2.6 
mm61, a 3 cm aneurysm will take over five years to reach 5.5 cm, indicating that even a modest 
reduction in aneurysm growth rate might forestall rupture by several years. At this time, 
however, there are no specific pharmacotherapeutics for AAA. Several drug classes have been 
studied, including beta-blockers25, statins26-29, and macrolide31 and tetracycline32-34 antibiotics. In 
particular, use of statins, roxithromycin and doxycycline have been associated with reduced 
growth rates. These studies, however, were small (32-150 enrolled patients) and did not 
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necessarily achieve significance. Furthermore, none of these studies has yet been validated by 
a large clinical trial nor have reductions in mortality been demonstrated. Finally, it is not clear for 
currently available drugs whether the benefits in growth reduction will outweigh the risks/side 
effects of long-term use. Going forward, development of targeted therapies for AAA remains of 
great interest for research and the clinic. 
2.5 Genetic Studies for Identifying Complex Disease Loci 
 Despite extensive evidence for a genetic component in AAA, our understanding of the 
genetic components of AAA risk is still incomplete. In order to identify susceptibility loci for 
complex diseases like AAA, two general study designs have been employed: linkage analyses 
and genetic association studies. These studies are similar in concept in that they utilize naturally 
occurring sequence variants in order to identify these loci. Linkage analyses and genetic 
association studies rely on linkage and linkage disequilibrium (LD), respectively, two closely 
related but distinct genetic concepts. Linkage refers to the phenomenon of two genetic loci 
having an increased probability of being coinherited35. If there is a large distance between two 
loci on a chromosome, the chance of a crossing-over event occurring between the loci 
increases until all four possible combinations of alleles are equally likely to be inherited. In this 
instance, the proportion of gametes where recombination has occurred, also known as the 
recombination fraction (denoted θ), is 1/2, indicating independent segregation at the two loci. In 
contrast, for two loci in close proximity, the probability of a recombination event occurring 
between the two loci decreases, reducing θ to value between 0 and 1/2, indicating the two loci 
are in linkage. In contrast, LD is a population level concept. If an association exists between two 
loci at the population level, indicating that they have been coinherited over time from a distant 
ancestor, the loci are in LD. 
 Linkage is utilized in identifying disease loci by testing for linkage between a marker 
locus, usually a microsatellite marker, and a locus inferred by phenotype. Typically, the linkage 
statistic is expressed as a logarithm of odds (lod) score, which describes the likelihood that 
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observed data is the result of linkage rather than by chance, with a lod score of 3 commonly 
being defined as significant evidence of linkage. Several linkage methods exist for disease gene 
identification, including model-based and model-free analyses. For diseases with large families 
with affected members in at least three generations, model-based analyses, meaning a genetic 
model is specified, can be utilized. However, this approach is not appropriate for AAA, since 
many individuals diagnosed with AAA have parents who have died but children too young to 
develop an aneurysm, therefore making it difficult to find two, let alone three, generations living 
with aneurysms. Instead, model-free analyses using relative pairs can be utilized. For any two 
related individuals, it is possible to calculate the probability that they share an allele at a given 
locus identical by descent (IBD), meaning it is inherited from a common ancestral chromosome.  
Sibling relationships are particularly useful, since sharing of 0, 1, or 2 alleles IBD is possible, 
although other relationships such as cousin-cousin or child-grandparent can be used. 
Furthermore, sib-pair linkage analyses avoid the problem of multiple generations, since they 
require only two individuals from one generation of each family to be alive and willing to 
contribute to the study. Another problem with conventional model-based linkage analyses rely 
on the ability to accurately distinguish between affected and unaffected individuals. Since AAA 
is a late-age-at-onset disease, its incidence increases with age, a phenomenon known as age-
dependent penetrance. However, by using a type of sib-pair analysis known as affected sib-pair 
(ASP), problems of penetrance are avoided because all subjects being studied have been 
diagnosed with the disease. 
 Genetic association studies test for an association between an allele at a locus and a 
phenotype of interest within a population35,106. Genetic variants, in this case single nucleotide 
polymorphisms (SNPs), are genotyped in cases and controls and tests of association based on 
either genotype or allele frequencies are performed. If the frequency is statistically higher or 
lower in the cases, it is suggestive of a disease contributing or protective effect, respectively. 
Although the risk variant may be among the variants tested, often this variant has not been 
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identified. Instead, genetic association studies assume that an associated variant is in LD with a 
variant with true functional effects. Identifying the variants that contribute to disease risk 
requires an extensive analysis of the surrounding genomic sequences, which is often beyond 
the scope of the study. Tests of association can also be tested on the collective genotypes of 
several SNPs, or haplotype, since it is possible that the disease variant has been inherited over 
time with a group of SNPs on a section of a chromosome even though it may not be in LD with 
any single variant. 
 Two study designs are typically employed in genetic association studies, candidate gene 
approaches and the genome-wide association study (GWAS). Candidate gene association 
studies rely upon knowledge of the disease to identify genes plausible in the disease 
pathogenesis. These can be performed on a relatively smaller number of samples but will not 
identify variants in genes not known to be involved in the disease. On the other hand, GWAS 
requires even larger samples sizes, but can give a better understanding of the genetic 
architecture of diseases like AAA107. They are also more feasible than family-based studies for 
complex and deadly diseases such as AAA, since samples from extended families are not 
required. 
 Linkage analyses and genetic association studies each have advantages and limitations 
for identification of susceptibility loci. Since linkage analyses rely on familial aggregation of a 
disease, they are most useful for identifying a single locus (or group of interacting loci) that 
confers an increased risk of developing the disease35. Linkage analyses tolerate allelic 
heterogeneity, given that each risk variant is linked to the markers being tested, but can lose 
power with locus heterogeneity. In contrast, genetic association studies identify loci with the 
greatest contribution to disease risk in the population meaning that even variants conferring a 
high relative risk may not be detectable by association if they are rare. Conversely, low risk 
alleles may be detected if they are sufficiently common in the population (a minor allele 
frequency or MAF of greater than 10%). Association studies are robust to locus heterogeneity, 
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given that each locus has a sufficient population effect size, but the power to detect association 
may be significantly diminished in the presence of allelic heterogeneity.  
 Another disadvantage of genetic association studies is the higher potential for detecting 
spurious associations. Although false positives are certainly a concern with linkage analyses of 
complex traits, poor study design has the potential to create false positives in association 
studies. In particular, selection of controls for genetic association studies must be done with 
care. If independent samples of affected and unaffected individuals are used, factors such as 
population stratification can lead to mathematical associations that have no relationship to the 
underlying genetics of the disease being studied. Several approaches exist to address this 
problem, such as the use of spouses as controls in order to assure that case and control 
populations originate from similar ethnic and socioeconomic groups and share similar 
environmental factors. On the other hand, using “over-matched controls” or “supercontrols” will 
lead to difficulty in estimating the population attributable risk for the identified genetic variants. 
For this reason, some investigators advocate the use of population-based controls 
representative of the “general” population in the geographic area where the study is performed. 
In such studies, means for testing for potential stratification must be devised, and the so-called 
“genomic control” method has been used widely. In this approach, stratification can be tested by 
using genetic markers genotyped from other chromosomal regions 108. Alternatively, genetic 
markers known to show population differences can be used to show that the case and control 
populations do not differ at those markers even when an association is detected in a specific 
candidate gene being tested 109. 
 Sample size is also a concern for genetic studies. Generally, linkage analyses can be 
successful with fewer participants if one can obtain samples from families with many affected 
individuals. In contrast, association studies with fewer than 250 cases and 250 controls must be 
viewed with skepticism, because of a lack of statistical power. Even larger sample sizes are 
needed to identify variants with low allele frequencies or small relative risks and to investigate 
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gene-environment interactions. Table 3 shows power calculations demonstrating sample sizes 
necessary for a range of genetic risks and allele frequencies. Yet another potential complication 
is multiple testing, since most studies test a study population for multiple SNPs in several 
genes. In the case of a GWAS, a p-value of 5x10-7 or lower may be necessary to declare 
significant association after correcting for multiple testing. Two-phase studies are one strategy 
to reduce these complications; a preliminary screening of all variants is first carried out and 
used to rank the most significant variants to be tested in a second, independent population. This 
approach reduces the number of tests being done in the follow-up study. It must be emphasized 
that replication of the findings in an independent sample set is extremely important to eliminate 
false positives, although it is plausible that population-specific disease susceptibility alleles exist 
and that replication in a different ethnic population will not support the initial findings. Detailed 
recommendations on how to design, conduct, interpret and report on genetic association studies 
have been published recently107. 
2.5.1 Linkage Analyses of AAA 
 The use of linkage analysis to identify the genetic causes of lethal, late-age-at-onset 
diseases, such as AAA, has been difficult at best and has required several technological 
advancements to make the undertaking of such studies a reality. First, the use of noninvasive 
diagnostic imaging, such as ultrasonography screening studies carried out on the relatives of 
AAA patients, has allowed the identification of far more family members with AAA prior to 
rupture (Table 2). As a result, there are far more living, affected members available for genetic 
studies. Second, the identification of highly informative markers that can be easily analyzed 
using PCR has greatly enhanced the power of any linkage study. Third, the large number of 
linkage studies being performed on complex human diseases has refined and advanced the 
methods and models for linkage analyses. Fourth, there have been theoretical and applied 
advances in the linkage methodology itself 35. 
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 Two published reports have identified genetic loci linked to AAA using affected relative 
pair (ARP) linkage methods36,37. In the first published linkage analysis of AAA, Shibamura et 
al.36 used ARP linkage analysis to carry out a genome-wide screen, identifying linked regions on 
chromosomes 4 and 19. This analysis was carried out in two phases using 235 ARPs (213 
ASPs) from 119 families with at least 2 individuals per family (mean=3.2, range 2-7). In the first 
phase, genomic DNA from 75 ARPs (62 ASPs) in 36 families was used in a whole genome scan 
of 405 microsatellite markers. From the initial scan, 12 regions were identified as significant. In 
the second phase, additional microsatellite markers in those 12 regions were genotyped using 
the original set of ARPs and 160 additional ARPs (151 ASPs). The combined data were then 
analyzed using sex, number of affected individuals, and their interaction as covariates to allow 
for genetic heterogeneity. This analysis showed two regions with significant linkage, one on 
chromosome 19q13 with a lod score of 4.64 and another on chromosome 4q31 with a lod score 
of 3.73. A second study by van Vlijmen-van Keulen et al.37 also demonstrated linkage to 
chromosome 19q13 (non-parametric, multipoint linkage score = 3.95) by a different statistical 
method when analyzing 22 ASPs from three large Dutch families.  However, when 79 additional 
ASPs from 55 families were included in the analysis, this method failed to demonstrate linkage, 
likely due to genetic heterogeneity. As result of these linkage analyses, the chromosome 19 and 
4 loci have been designated as the AAA1 and AAA2 loci, respectively, in the Online Mendelian 
Inheritance in Man (OMIM) database.110. It is of interest to note that DNA linkage studies on 
TAAD have identified completely different genetic regions suggesting that the two aortic 
aneurysm subtypes are genetically different111.  
2.5.2 Genetic Association Studies of AAA 
 There have been a fair number of genetic association studies for AAA, many of which 
have been summarized elsewhere16. Most studies have used a candidate gene approach by 
selecting SNPs from genes with known or putative function in AAA, whereas only one genome-
wide association study has been published to date112. It is important to note that many early 
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association studies were small and did not have adequate power to definitively exclude or prove 
an association. Furthermore, in several instances, evidence of association in one population has 
not been replicated by studies in a different population. Possible explanations for these 
discrepancies are variation in genetic risk factors between populations, and false positives or 
false negatives from small sample sizes (type I and II errors). 
 Candidate genes that have been studied for association in AAA are involved in a variety 
of physiological and disease processes. Genes involved in cardiovascular function, extracellular 
matrix composition and breakdown, and immunity have all been investigated. The best evidence 
for association is probably with cardiovascular risk genes. The largest genetic association study 
to date on AAA demonstrated a significant association with a variant on chromosome 9p21 
using 2017 cases and 16,639 controls (OR=1.31, p=1.2x10-12)38. A study of polymorphisms in 
the renin-angiotensin system (RAS) by Jones and colleagues showed significant association 
with the C allele at amino acid 1166 of the angiotensin II receptor 1 (AGTR1) gene using 1226 
AAA cases and 1723 controls from three geographically distinct populations from New Zealand, 
Australia and the United Kingdom39. Additionally, the same study demonstrated marginal 
association with a deletion in intron 16 of angiotensin converting enzyme (ACE). Association 
with these polymorphisms was also reported in a meta-analysis, as was association with 
polymorphisms in interleukin 10 (IL10), MMP3 and 5,10-methyltetrahydrofolate reductase 
(MTHFR) genes113. Two studies using 250 cases and 250 controls from the Italian population 
reported evidence of association with the ACE polymorphism114 and with a variant in the nitric 
oxide synthase 3 (NOS3) gene115. 
 Despite identification of some risk variants for AAA, there is still much to be identified 
concerning AAA genetic risk. Evidence of association with several polymorphisms has not been 
verified in large study populations. Even where there is strong evidence, the relative risk for 
each polymorphism is relatively low, suggesting that there are many more similar 
polymorphisms to be identified. Several of these polymorphisms are also non-specific for AAA; 
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the 9p21 variant has been associated with CAD and IA38 and RAAS system variants have been 
extensively studied in other cardiovascular diseases such as heart failure116,117, CAD118, 
stroke119. 
 New strategies will be necessary to identify additional variants in the future. GWAS 
offers some promise; the one published GWAS studying AAA identified association with SNPs 
near the gene contactin 3 (CNTN3), which had not been previously indicated in AAA112. 
Evidence of association was replicated by the authors using an independent set of cases and 
controls. Another group failed to replicate the original findings in a separate population, but did 
identify nominal association in different SNPs within CNTN3. These results did not reach 
genome-wide significance, however, suggesting additional study may be necessary at this 
locus120. An alternative strategy for identifying risk alleles is combining linkage and association 
results. This approach has been successful in identifying risk variants for several diseases, such 
as prostate cancer40, osteoporosis43, schizophrenia42 and myocardial infarction41. Linkage 
results are less susceptible to confounding factors such as population stratification so even 
evidence of a weak association within a linked region is more likely to represent a real genetic 
effect. Furthermore, by using families enriched for the aneurysm phenotype, variants in linked 
regions may be more specific for the aneurysm phenotype. Variants within linked regions are 
more likely to be rare, making them of less utility at a population level. 
2.6 Mechanisms of AAA Formation 
2.6.1 The Immune System in AAA 
 Inflammation and the immune system has long been recognized in a subset of 
aneurysms known as inflammatory aneurysms (IAAA) but the contribution of the immune 
system to the pathogenesis of nonspecific AAA was recognized only within the past two 
decades121. The first description of immune infiltrates in nonspecific AAA was a study by Koch 
and colleagues in 199055, where the presence of macrophages and T- and B-lymphocytes in 
AAA tissue was demonstrated by staining with the cell specific markers CD11c, CD3 and CD19, 
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respectively. They were also first to observe that, despite the presence of atherosclerotic 
changes in aneurysm tissue, AAA and aortoocclusive disease (AOD) have distinct 
immunological phenotypes. Both diseases have similar intimal layers, with atherosclerotic 
plaques containing macrophage-derived foam cells interspersed with T-cells and a small 
number of dendritic cells and macrophages. AAA, however, has the additional transmural 
component, with significant adventitial inflammation infiltrating into the outer media. 
 Conventionally, transmural inflammation in vascular disease has been explained in an 
“inside out” manner, meaning that inflammatory cells infiltrate into the aortic wall from the intima. 
This is supported by the presence of neovascularization at the interface of atherosclerotic 
plaque and the media of the aorta where vasa vasorum are scarce122. This neovascularization 
could plausibly provide a route for infiltration of the media and adventitia leading to aneurysm 
formation. Growing evidence also points to an “outside-in” component of AAA 
inflammation123,124. This hypothesis states that vascular injury may cause inflammatory cells to 
accumulate in the adventitia that then work their way towards the lumen. An example of this 
process is restenosis following balloon angioplasty where early inflammation occurs in the 
adventitia and then progresses inwards124. Following injury, neovascularization occurs in the 
outer layers of the vessel, subsequently allowing greater recruitment of immune cells into the 
adventitia. This may be particularly applicable to AAA development, as the abdominal aorta has 
fewer vasa vasorum and may therefore be more prone to an angiogenic response to injury and 
greater immune infiltration. Similar to injury from balloon angioplasty, a recently reported porcine 
model of AAA requires balloon injury of the aorta as well as luminal treatment with elastase to 
induce aneurysm formation125. This indicates that adventitial injury may be necessary in addition 
to intimal inflammation for AAA formation. 
2.6.2 Expression Profiling of AAA Tissue 
 Whole genome expression profiling of AAA tissue confirms the importance of the 
immune system in AAA pathogenesis. Expression profiling is the characterization of a tissue by 
  
26 
identifying which genes are expressed in it and how highly they are expressed. Expression 
profiling can be done through several methods, but the current standard is whole-genome 
microarray platforms available from several manufacturers. Microarray experiments are 
expensive but much cheaper per gene and use less genetic material. Microarray experiments 
compare gene expression patterns between tissues or cells, such as between an aneurysmal 
aorta and a non-aneurysmal one. The changes in gene expression can then be used to identify 
biological processes relevant to the disease being studied. This can be done by categorizing 
differentially expressed genes by function, such as GO category45 or KEGG pathway46, and 
determining the categories or pathways that are statistically enriched. 
 Lenk et al. reported the only whole genome comparison of AAA and control aorta using 
two different microarray platforms48. From a reference list of 18,057 genes common to the two 
microarrays, 3,274 genes were differentially expressed between AAA (n = 7) and control tissue 
(n = 7), even after correction for multiple testing. Differentially expressed genes included ones 
previously identified in AAA tissue, including several proteases and cytokines, as well as new 
ones such as RUNX3 and SOST. Analysis of the differentially expressed genes using KEGG 
pathways showed several pathways related to immune function to be enriched in AAA, such as  
“leukocyte transendothelial migration” and “T cell receptor signaling pathway”. 
 Another whole genome microarray study on AAA by Choke and colleagues used pooled 
RNA samples from tissue at the site of rupture from 10 aneurysms and compared this with 
pooled RNA isolated from the anterior sac of the same aneurysms47. One hundred thirty-nine 
genes were identified as statistically different (p<0.005) with a fold change of 2.5. Genes 
involved in immune response and signal transduction were the most significantly enriched, 
including selectin E (SELE), PTGS2 (also known as COX2), and interleukins 6 and 8 (IL6, IL8). 
A third whole genome microarray comparing gene expression in the blood of AAA patients and 
matched controls has also been published, finding changes in genes associated with lipid 
metabolism and oxygen transport49. 
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 Although microarrays are potentially powerful tools for studying diseases like AAA, they 
are also subject to some limitations. First, similar to any gene expression analysis, sample 
replicates are necessary to account for sample variability. This can be problematic if the cost of 
the microarrays is prohibitive or if obtaining multiple tissue samples is difficult. Another limitation 
is incomplete annotation of gene function; GO categories and KEGG pathways are only useful 
for genes with known function. Additionally, microarrays, as well as other gene expression 
methods, only test for levels of mRNA and may not represent what is occurring at the protein 
level. Therefore it is important that gene expression findings be confirmed using different 
methods such as immunohistochemistry or protein blotting. Finally, there are several statistical 
considerations for the analysis of microarray data such as how to define differential expression 
or account for the large number of false positives generated when looking at thousands of 
genes. Time-course and other longitudinal analyses require additional considerations, both with 
respect to significance analysis and in defining what constitutes an expression pattern of 
interest. 
2.6.3 Inflammatory Cells in AAA 
 The immune response in AAA is diverse with inflammatory infiltrates containing a varied 
population of leukocytes, including B- and T- lymphocytes, as well as natural killer and natural 
killer T cells, macrophages, dendritic cells, mast cells and polymorphonuclear leukocytes 
(PMNs). By far the most numerous are lymphocytes, which are located throughout the vessel 
wall. Most of these are T-cells, which can be found in both the adventitia and intima, but there is 
also a large proportion of B-cells found in the adventitia, another feature that distinguishes AAA 
from AOD, which has minimal B-cell involvement56. NK and NKT cells have also been identified 
in smaller numbers, but may have an important role in aneurysm pathogenesis (see below)56,57.  
 Characterization of the lymphocyte populations in aneurysm tissue has demonstrated a 
role for adaptive immunity in AAA56,57,126. Consistent with observations from 
immunohistochemical staining, a majority of lymphocytes identified by flow cytometry are T-
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lymphocytes (~58-80%). Comparison with peripheral blood T-cells shows a similar ratio of 
CD4/CD8 positive T-cells, with approximately two thirds of T-cells from AAA tissue expressing 
CD4. Significantly more aneurysmal T-cells than peripheral blood T-cells express CD69 and 
HLA-DR, which are markers of activation by antigen exposure56,126. Additionally, an increased 
number of aneurysmal T-cells exhibit a memory phenotype, as demonstrated by CD45RO
+ 
CD45RA
–
 staining56,126. Findings in B-lymphocytes are similar, with increased cells in AAA tissue 
staining for the activation markers CD69 and CD80 and the memory marker CD2756,57. This 
activated, memory phenotype suggests an ongoing, antigen-driven response may be 
responsible for driving inflammation in AAA. This is further supported by the differences 
between AAA and peripheral blood lymphocytes, which show that specific lymphocyte 
populations are recruited into the aneurysm wall56.  
In histological sections, adventitial lymphocytes can be found arranged as lymphoid follicle-like 
structures, composed of B-cell germinal centers surrounded by T-cells56,127. Bobryshev and 
colleagues127 found these structures in just over 50% of AAA tissues examined (17/31) and 
identified them as hypertrophied vascular-associated lymphoid tissue (VALT), which are 
analogous to mucosa-associated lymphoid tissue (MALT) in the gut and lungs. Consistent with 
the role of MALT in antigen presentation, cell-to-cell contacts between T-cells and dendritic cells 
were identified by electron microscopy, further supporting the possible role for an antigen-driven 
immune response in AAA. 
 Given the evidence for AAA being an antigen-driven disease, it has been suggested that 
aneurysms are a chronic autoimmune disorder in which an aortic antigen drives inflammation. A 
study by Tilson showed IgG from aneurysm samples reacting to an 80 kDa protein found in the 
aortic wall128. Sequence analysis of this protein showed homology to microfibrillar proteins 
present within bovine and porcine aortas. Immunohistochemical staining using these AAA-
derived IgG showed binding to a collagen associated protein in the adventitial ECM129. These 
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results suggest that inflammation directed against this protein or other constituents of the aortic 
wall may contribute to AAA development. An alternative hypothesis is that chronic infection, 
such as with Chlamydia pneumoniae or cytomegalovirus, may drive the immune response in the 
AAA wall, either directly by the presence of the pathogen or through molecular mimicry. C. 
pneumoniae has been extensively researched, with studies producing a variety of evidence 
suggesting its presence in the aneurysm wall130-138, although other studies have failed to detect 
C. pneumoniae DNA139,140 and C. pneumoniae IgG titers do not correlate with AAA141,142. The 
combined results of these studies indicate that C. pneumoniae is likely not necessary or 
sufficient for AAA formation but that it may play a role in sustaining the immune response in 
aneurysmal tissue. 
 If AAA is antigen-driven, one would expect to detect a limited antibody or T-cell 
repertoire directed against these antigens. PCR-based assessments of the TCR β-chain and 
immunoglobulin heavy chain genes demonstrating unrestricted usage of the gene repertoires 
suggest this may not be the case143. In contrast, a study by Platsoucas and colleagues showed 
multiple identical α, β, γ, and δ chain transcripts in AAA tissue by cloning and sequencing of the 
TCR repertoire, indicating at least some degree of clonality, since it is unlikely to observe 
multiple clones with the same sequence by chance121,144. 
 Given that CD4
+
 helper T-lymphocytes are the predominant leukocyte in aneurysms, 
another question that has been posed by investigators is whether this represents a Type 1 (Th1) 
or Type 2 (Th2) T-cell response. Conventionally, Th1 cells drive cell-mediated immunity by 
stimulation of macrophages and CD8+ T-cells and Th2 cells stimulate B-cells to produce 
antibodies, including IgA, directed at specific antigens, for which evidence of both exists in AAA. 
Based upon histological findings, the significant macrophage presence in AAA tissue might 
suggest that there is a Th1 response driving macrophage recruitment. Conversely, replicating B-
cells within VALT and their colocalization with dendritic cells, as well as the presence of plasma 
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cells with Russell bodies, provide evidence for a Type 2 response58,127, although the production 
of opsonizing antibodies by B-cells is a characteristic of Type 1 responses. These responses 
also have distinct cytokine profiles. Galle and colleagues126 used quantitative RT-PCR to study 
expression of the Th1 and Th2 cytokines IFNG and IL4, respectively, and found increased IFNG 
expression in aneurysmal compared to control tissue but no increase in IL4, suggesting a Th1 
response. Additionally, expression of the Th1-associated transcription factor T-bet (TBX21) was 
also significantly increased whereas GATA3, a Th2-associated transcription factor, was not. In 
contrast, Schönbeck and colleagues145 found significant amounts of Th2 cytokines IL4 and IL10 
by immunohistochemistry and western blotting but no evidence of a Th1 response. To explain 
these conflicting results, Shimizu and colleagues146 have proposed a model that involved a Th1 
response early in atherogenesis and a shift to a Th2 response later in aneurysm development. 
One complication, however, is that some studies do not distinguish between the intimal and 
adventitial infiltrates, and cytokine production might vary from layer to layer.  
 More comprehensive studies of cytokines in AAA have addressed the question of T-cell 
response in greater depth. Lindeman, et al. used several protein and mRNA detection methods 
and found Th1 cytokine genes IL2, IFNG, IL1A, and IL1B as well as Th2 cytokine gene IL13 
were significantly increased in AAA over AOD147. Another study demonstrate ex vivo T-cells 
production of primarily Th1 cytokines but also Th2 cytokine IL557. Array-based analyses add 
further evidence to this hypothesis. A cytokine protein array study by Middleton and 
colleagues148 comparing AAA versus controls found evidence of increased expression of Th1 
cytokines TNF, LTA, and CCL2 and increased Th2 cytokine IL10, a result that was fairly 
consistent with the microarray expression profile in Lenk, et al48. Since IL10 is also produced by 
some Th1 cells, this suggests the Th1 response is predominant. Neither study, however, found a 
statistically significant increase in levels of Th1 cytokines IFNG, IL2, or CSF2. In summary, these 
combined results suggest that T-cell response in AAA may vary from individual to individual or 
by the progression of the disease, or that AAA T-cells represent an intermediate phenotype 
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capable of producing both Th1 and Th2 cytokines57. 
2.6.4 The Role of Other Leukocytes 
 Other non-lymphocytic immune cell types have been implicated in AAA. As producers of 
proteolytic enzymes such as MMPs and cathepsins, macrophages have been considered 
particularly important. They are primarily found in the intima, but are also detectable in the 
adventitia. By flow cytometry, macrophages represent only a small percentage (~2%) of 
leukocytes, although this may be an artifact of cell isolation from tissue56,57. In addition to their 
direct involvement in ECM breakdown, macrophages also produce several pro-inflammatory 
cytokines and chemokines including IL1B, TNF, CCL2 and IL8, all of which show increased 
production in aneurysmal tissue48. Finally, macrophages produce additional biologically relevant 
molecules such as prostaglandins, which can stimulate IL1B synthesis and produce modulating 
effects on SMCs, and syndecan-1, a proteoglycan with functions in tissue repair122,149,150. 
 Another cell type that may have a small yet critical role in aneurysm development is the 
mast cell. Although mast cells are typically associated with IgE mediated immunity and allergies, 
they produce several substances, such as histamine and heparin that could help drive 
inflammation in AAA. Mast cells are increased in AAA tissue compared with control aortas, and 
are found in the adventitial layer associated with microvessels59,151,152. Treatment with a mast 
cell derived peptide, adrenomedullin, decreases collagen production in cultured fibroblasts from 
AAA59. Animal models also suggest a role for mast cells in AAA pathogenesis, as aneurysm 
formation is inhibited by mast cell knockout in both the elastase and CaCl2 mouse models of 
AAA153. 
2.6.5 Proteolytic Enzymes in AAA 
 Infiltrating immune cells, including mast cells, macrophages and PMNs, as well as SMCs 
are able to secrete a variety of enzymes that degrade the ECM. The most studied are the 
MMPs, and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), although other 
families of enzymes, such as the cathepsins, serine elastases and plasmin, have been studied. 
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The MMPs are a family of related enzymes that break down ECM components including elastin 
and collagen, although each MMP targets a different repertoire of substrates123,154,155. MMPs 
have the necessary function of degrading damaged ECM so that new matrix can be 
regenerated, but can also quickly cause tissue damage if unregulated. Therefore, MMPs are 
regulated by several mechanisms: by transcription in response to cytokines and growth factors, 
by secretion in inactive zymogen form, and by inhibition by TIMPs123. TIMPs are secreted 
proteins that bind to activated MMPs. MMPs and TIMPs are often secreted together so as to 
prevent excess MMP activity. Immunohistochemical analysis of AAA tissue shows that the MMP 
to TIMP ratio is increased, suggesting that the balance between the two types of proteins 
influences aneurysm development156,157. 
 MMP2 and MMP9, also known as gelatinase A and B, respectively, are two MMPs which 
specifically cleave gelatin, types IV and V collagen, and fibronectin155. More importantly, MMP2 
and MMP9 are able to efficiently cleave elastin. Elastin is the most abundant protein in the 
abdominal aorta, accounting for 30% of the aorta by weight122. The elastin structure of a blood 
vessel is formed during development and elastin production does not continue in adulthood122. 
Under normal physiological conditions elastin is quite stable158, making the breakdown of elastin 
in aneurysms particularly striking. The primary structural role of elastin is load bearing; it 
provides distensibility in response to hemodynamic stress, therefore helping the vessel to 
maintain its shape. In contrast, collagen, the other major ECM component, provides tensile 
strength and stiffness to the aorta. A set of experiments by Dobrin and colleagues demonstrated 
the biophysical effects of elastin and collagen loss in an arterial tissue159. Under perfusion at 
physiological pressures, arteries treated with elastase exhibited dilatation and stiffening, 
whereas collagenase-treated arteries did not dilate but ruptured. Arteries treated with both 
enzymes dilated rapidly and then ruptured. Given that the elastin in a structurally sound aorta 
maintains vessel shape even under hypertensive conditions, its degradation appears to play a 
key role in aneurysm growth. Collagen loss in aneurysms, which is typically not detected as 
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early in aneurysm growth, appears to have a more important role in aneurysm rupture. This is 
supported by the evidence that mutations in the gene for type III procollagen (COL3A1) lead to 
the type IV form of the Ehlers-Danlos syndrome, the hallmark of which is a rupture of hollow 
organs such as the aorta, uterus or bowel160. 
 Multiple studies examining MMP2 and MMP9 transcripts and activity have found them to 
be increased in AAA tissue161-164. There is some variability in findings, and of the two, MMP9 
has been more consistently identified as increased. Additionally, increased MMP9 activity may 
be more specific to AAA as compared with MMP2162. Immunohistochemical analysis reveals 
most MMP9 expression in AAA is derived from infiltrating macrophages, although evidence 
exists for SMC production of MMP9163,165,166. Wilson and colleagues have also observed that 
MMP9 levels are increased near the site of aneurysm rupture167. Several studies have shown 
increased levels of MMP9 in the blood of AAA patients168,169, which are decreased following 
surgical repair. These levels do not, however, have a strong predictive value for identifying the 
presence of an aneurysm. In contrast to MMP9, MMP2 may have a more generalized role in 
vascular inflammation. MMP2 expression is upregulated in aneurysms, particularly in small 
ones. It is produced by both resident SMCs and macrophages, and can be found in normal 
aorta as well as AOD tissue163. Increased MMP2 production and activation may therefore be a 
tissue reaction to inflammation, as evidenced by the observation that SMC MMP2 production 
increases in the presence of inflammatory cells163. Goodall and colleagues also reported that 
MMP2 levels were increased in remote vasculature of AAA patients, suggesting that the 
increase is part of a systemic response170.  
 In addition to ECM breakdown, MMP2 and MMP9 may also have roles in ECM signaling. 
Johnson and colleagues showed that deficiency of both proteins led to decreased SMC invasion 
in vitro171. Additionally, it was found that MMP9 may function in the interaction between SMCs 
and ECM proteins since Mmp9 knockout mice (Mmp9
–/–
), but not Mmp2
–/– 
mice, had an impaired 
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ability of SMCs to reorganize collagen171. Goodall and colleagues172 confirmed that MMP2 might 
increase SMC migration by showing that SMCs from AAA patients have higher levels of MMP2 
and increased invasiveness in vitro.  
 Several other MMPs have also been implicated in AAA pathogenesis. MMP12, also 
known as metalloelastase, has been studied because of its ability to degrade elastin. 
Comparison of AAA and control tissue has shown that MMP12 concentration is increased in 
AAA tissue, particularly in macrophages and in association with elastin fibers173,174. MMP8, a 
collagenase, is found at the site of aneurysm rupture, which is consistent with the hypothesis 
that collagen breakdown is a necessary condition for AAA rupture. Two MMPs involved in 
activation of other MMPs, namely MMP3 and MMP14, are also present in AAA tissue. MMP3 is 
a known activator of MMP9 and is increased in AAA compared with AOD175,176. In contrast, 
MMP14, which is also increased in AAA tissue, is known to activate MMP2 and colocalizes with 
it in AAA tissue173,177. Finally, there are more recently discovered MMPs that have yet to be 
evaluated in AAA tissue. 
 In addition to the MMPs, there is evidence of other families of proteases functioning in 
AAA tissue. For instance, plasmin (PLG), a known activator of MMP3, has been found in AAA 
tissue122,176. Of particular interest are cathepsins, a family of cysteine proteases that also have 
the ability to degrade elastin fibers. Immunohistochemistry has identified cathepsins S, K and L 
in the atheroma and intima of AAA tissue178,179. Similar to MMPs, the cathepsins were found in 
macrophages and SMCs exposed to inflammatory stimuli, such as interferon gamma (IFNG) 
and interleukin-1 beta (IL1B)178,179. Additionally, as with MMPs, cathepsins might have a role in 
angiogenesis, as inhibition of cathepsin S reduced endothelial cell invasion in culture. 
2.6.6 Oxidative Stress 
 Oxidative stress may also contribute to AAA pathogenesis. Reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) have been implicated in the pathology of several 
conditions, such as Alzheimer’s disease and atherosclerosis180,181. Supporting a role for 
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oxidative stress in AAA is the decreased expression of three enzymes responsible for 
eliminating ROS, superoxide dismutase, glutathione peroxidase, and glutathione reductase, in 
AAA tissue182. Simultaneously, inducible nitric oxide synthase shows increased expression. 
 Multiple cell types contribute to production of ROS and RNS in AAA tissue. 
Macrophages in particular have NADPH oxidase and myeloperoxidase activity that can produce 
large amounts of O2
– 
and hypochlorous acid (HOCl), which in turn oxidize LDL and cause tissue 
damage182. Angiotensin or TNF can stimulate SMCs to increase ROS production through 
NADPH oxidase183. Not all sources are driven by inflammation, however, as SMCs can also 
produce ROS in response to pulsatile forces182.  
 ROS and RNS could have several effects on aneurysm formation182. First, they could 
induce cytokine production that then contributes to immune cell infiltration. Alternatively, they 
can lead to activation of NFKB, an inflammatory transcription factor implicated in AAA. ROS can 
also have an effect on the ECM through activation of MMP2 and MMP9. Finally, ROS could 
possibly lead to SMC apoptosis, although this is debatable as ROS have been shown to 
increase SMC proliferation. 
2.6.7 Smooth Muscle Cell Apoptosis 
 The loss of SMCs via cytotoxicity-induced apoptosis may also lead to weakening of the 
AAA wall. Although fewer in number than CD4+ T-cells, cytotoxic CD8
+ 
T-cells still represent a 
significant proportion of lymphocytes in the aortic wall56,57. Similarly, NK and NKT cells comprise 
a small number of lymphocytes by flow cytometry, but both cell types have been detected by 
immunostaining in aneurysm tissue60, as have the apoptotic mediators perforin and Fas184. 
When isolated from AAA plaques, NKT and CD4+ T-cells induce differential effects in vascular 
SMCs, with the T-cells enhancing proliferation and NKT cells increasing apoptosis185. 
Additionally, the number of peripheral blood NK cells is increased in AAA patients compared to 
controls186. 
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 An important role for cytotoxic lymphocytes is further supported by microarray analysis. 
Of the immune-related KEGG pathways identified by Lenk, et al., “Natural Killer Cell Mediated 
Cytotoxicity” was the statistically most enriched pathway in AAA tissue compared to non-
aneurysmal aorta tissue48. This pathway, which is not specific to NK cells, contains the cell 
surface markers, downstream signaling genes and effector molecules that have been shown to 
be involved in the activation and cytotoxic action of lymphocytes. Regardless of cell type 
expressing these genes, the degree of enrichment suggests that cytotoxicity may be more 
important in AAA tissue than previously thought. It is also possible that the effector molecules 
have additional roles in AAA tissue. This is supported by a recent study that showed that 
granzyme b (GZMB), a serine protease that can induce apoptosis in concert with perforin, has 
the ability to degrade ECM proteins187. Additionally, TNF, an inflammatory cytokine upregulated 
in this pathway, has been increasingly implicated in vascular disease188. Given these various 
roles in AAA pathogenesis, genes in this pathway may be good targets for AAA therapies. 
2.7 Hemodynamics and Site-Specificity of Aneurysm Formation 
 Despite our growing understanding of immunity and its role in AAA pathogenesis, the 
mechanisms of the initial inflammatory infiltration in the aneurysm wall are not well understood. 
The structure, hemodynamics and native cells of the aorta can all contribute to making the 
tissue susceptible to aneurysm formation. For example, aortic SMCs display increased 
polyploidy and gene expression with age189. The decreased susceptibility to AAA in women 
indicates that sex hormones may alter biology of the aorta190, a hypothesis supported by work in 
human tissues191 as well as animal models192-195. SMC and endothelial gene expression is 
altered by hemodynamic force196,197. Early phenotypic changes to SMCs in experimental AAA 
further suggest that cells of the aorta may contribute to initiating an inflammatory response198. 
2.7.1 Aortic Regional Variation and Disease Relevance 
 It is well established that vascular diseases, such as atherosclerosis and vasculitides, 
display site-specific patterns of formation. Similarly, aneurysms usually develop in a limited 
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number of blood vessels, including abdominal and thoracic aorta, intracranial vessels, and 
popliteal arteries. There is some overlap in susceptibility to aneurysmal and atherosclerotic 
disease, but not all vessels that are prone to atherosclerosis develop aneurysms, indicating that 
factors specific to those vessels are important in aneurysm development122. Furthermore, the 
abdominal aorta may be distinct even from other vessels that develop aneurysms; most AAA 
patients are unlikely to present with a second aneurysm. AAA clusters into different families 
than intracranial aneurysms (IA) and TAAD, suggesting that the abdominal aorta has 
characteristics that differentiate it from other arteries, including other regions of the aorta. 
Additionally, TAAD patients are much younger and there is a much smaller gender difference 
(1.7:1 male-female ratio). TAADs also display different pathobiology, being characterized by 
medial necrosis also known as “Erdheim’s cystic medial necrosis”, mucoid infiltration, and cyst 
formation with elastin degradation and vascular smooth muscle apoptosis199. Finally, gene 
expression in TAADs differs from AAA. An early cDNA array study by Absi et al.200 determined 
the genes that are differentially expressed between thoracic aorta and TAAD and then 
compared these with genes with altered expression in AAA. This analysis was able to show that 
AAA is characterized by changes in genes related to inflammation whereas TAA is 
characterized by changes in cell survival, proliferation and programmed cell death. 
 Structurally, the abdominal aorta displays characteristics that distinguish it from the 
thoracic aorta. One key distinguishing feature is the number of elastic lamellae; approximately 
40-80 elastic lamellae may be found in the thoracic aorta depending on location whereas the 
abdominal aorta has approximately 30201. There is a corresponding decrease in elastin and 
collagen per luminal surface area between the thoracic and abdominal regions50. In addition, the 
ratio of elastin and collagen changes in the aneurysm susceptible infrarenal aorta, as there is 
greater decrease in elastin content from the suprarenal to infrarenal aorta than in collagen 
content. Another key difference is that relative to other species, the human abdominal aorta 
deviates in the expected number of elastic lamellae. A study by Wolinsky and Glagov201 
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examining the elastic lamellae of thoracic and abdominal aortas in ten species observed that 
human abdominal aorta had fewer elastic lamellae than would have been predicted by aortic 
diameter or wall thickness. The most important consequence of this lack of elastic lamellae is 
that human abdominal aorta lacks vasa vasorum. In a pattern consistent across species and 
aortic segment, the innermost 29 lamellae constituted an avascular zone, receiving nutrient and 
gas exchange by diffusion from the lumen, whereas vasa vasorum were present in additional 
lamellae. Since the abdominal aorta would be predicted to contain more than 30 lamellae, and 
therefore vasa vasorum, the outermost lamellae would be expected to experience relative 
hypoxia. Furthermore, compared to other species with avascular aortas, the tension per lamellar 
unit in the human abdominal aorta is much higher. Functionally, this may result in the outer 
media of human abdominal aorta being more susceptible to stresses that lead to aneurysm 
formation. 
 The blood flow through the abdominal aorta also displays characteristic patterns 
associated with vascular injury. Due to its narrowing diameter and branch points, the blood flow 
through the abdominal aorta creates regions of turbulent flow with decreased shear stress, or 
blood flow directly over the endothelium. Vessels with turbulent flow are associated with 
atherosclerosis formation, and the high prevalence of atherosclerosis in the abdominal aorta is 
consistent with this observation. Further changes to the aortic geometry may increase the risk of 
aneurysm formation. For instance, the geometry of the abdominal aorta may change with age, 
altering hemodynamics22. On the other hand, allograft studies exchanging abdominal aorta with 
thoracic aorta or pulmonary artery have demonstrated that the development of atherosclerosis 
was dependent on the tissue of origin, not the vascular site. 
 Differences in embryological origin between the abdominal and thoracic aorta may 
further explain the site-specificity of AAA (and TAAD)202. Le Lievre and colleagues showed that 
the SMC lineages of the ascending thoracic and abdominal aorta differ, with origins in 
neuroectoderm and mesenchyme, respectively51. Although similar, these two lineages showed 
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an important difference in response to transforming growth factor beta (TGF-β; TGFB1) 
signaling203, which has been implicated in the Marfan syndrome and TAAD111, perhaps 
indicating a difference in media formation. 
2.7.2 HOX Genes and the Vasculature 
 The abdominal aorta may also exhibit site-specific gene expression. One such group of 
genes that shows spatial expression in the vasculature is the homeobox HOX family of 
transcription factors. The common feature of the HOX genes is the homeodomain, a 61 amino-
acid DNA-binding motif. There are a total of 38 HOX genes in four chromosomal loci (HOXA@, 
HOXB@, HOXC@, and HOXD@). Each of these loci contains 9-11 genes that are divided into 
13 paralogous groups. During development, HOX genes exhibit a unique temporospatial 
expression pattern known as colinearity, where the 3’ HOX genes, or genes from lower number 
paralogous groups such as HOXA1, HOXB1 or HOXB2, are expressed rostrally early in 
development, with each more 5’ group being expressed progressively later and more caudally. 
In adult tissues, HOX gene expression continues in spatially dependent manner, suggesting a 
role in maintaining tissue identity. Microarray analyses of SMCs204, fibroblasts205-207 and bone 
progenitor cells208 have shown that a cell’s tissue of origin can be identified by its specific HOX 
gene profile. The HOX gene expression profile appears to be intrinsic to the cells rather than a 
consequence of external factors, as expression of HOX genes in fibroblasts was not altered by 
either 35 passages in vitro or by coculturing cells with differing HOX gene expression207. Using 
Hoxa3- and Hoxc11-lacZ transgenic mice, Pruett and colleagues209 showed that the embryonic 
expression pattern of Hoxc11 and Hoxa3 is maintained in the vasculature until at least 1 year. 
 Since they can directly affect the expression of many genes and pathways, transcription 
factors such as the HOX genes are useful for studying in complex diseases such as AAA. The 
importance of transcriptional networks in AAA is illustrated by a recent study examining 
transcription factor binding sites in genes that are upregulated in AAA tissue. Binding sites for 
nuclear factor kappa B (NFKB) and 7 transcription factors from the v-ets erythroblastosis virus 
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E26 oncogene homolog (ETS) family were identified as overrepresented among the upregulated 
genes. These results were consistent with previous studies showing that decoy oligonucleotides 
against ETS1 and NFKB inhibit210 and reverse211 aneurysm progression in animal models. 
Although the vascular functions of HOX genes are not fully understood, they can regulate 
angiogenesis212,213, respond to inflammatory stimuli214,215 and target several genes relevant to 
AAA, including MMPs216, NOS3217, and SPP1218-220. 
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CHAPTER 3 – MATERIALS AND METHODS 
 
3.1 Human Research Compliance 
 The experiments described herein, including collection and use of human tissue 
samples, were conducted with the approval of the Institutional Review Board of Wayne State 
University, Detroit, Michigan, and the research was carried out in compliance with the Helsinki 
Declaration. 
3.2 Genetic Association and Sequencing of Functional Positional Candidate Genes 
3.2.1 Human Samples for Genotyping and Sequencing 
 Peripheral blood or skin fibroblasts were obtained for isolation of genomic DNA or RNA, 
respectively, from AAA cases, relatives of AAA patients from multiplex families, and unaffected 
controls. AAA cases used in genotyping (n = 487; 79% male) were collected at the University of 
Pittsburgh (n = 103), the University of Liege in Liege, Belgium (n = 178), or Dalhousie University 
Hospital in Nova Scotia, Canada (n = 206). Control samples (n=424) were spouses or patients 
at the same hospital and were collected from Belgian (n = 269) and Canadian (n = 155) 
populations at the latter two collection sites. Genomic DNA or RNA samples representing 
familial AAA cases, sporadic AAA cases and unaffected controls were used in sequencing of 
candidate genes (Tables 4 and 5). 
3.2.2 DNA Isolation and Whole Genome Amplification 
 Genomic DNA used in genotyping and sequencing was isolated from peripheral blood as 
previously described221. Genomic DNA was amplified by strand displacement amplication222 with 
Phi29 polymerase using the Genomiphi Kit from Amersham (GE Healthcare Biosciences, 
Piscataway, NJ). One microliter (10ng) of sample DNA was combined with 9 µl of sample buffer 
according to kit instructions, heat denatured, and mixed with 1 µl of polymerase diluted in 9 µl of 
reaction buffer. Amplification was carried out in thermal cycler for 17 hours at 30°C, followed by 
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10 minutes at 65°C and cooling to 4°C. Dilutions of 1:5 and 1:100 were prepared for storage at -
80°C and for use in polymerase chain reactions (PCR), respectively. 
3.2.3 RNA Isolation and cDNA Synthesis 
 RNA was isolated from skin fibroblasts as previously described73. cDNAs were prepared 
from RNA samples using SuperScript III First-Strand Synthesis Supermix from Invitrogen. Two 
microliters of RNA diluted to 0.5 µg/µl was added to 10 µl 2X RT reaction mix, 2 µl RT enzyme, 
and 6 µl diethylpyrocarbonate (DEPC) treated water. Samples were incubated at 25°C for 10 
minutes, followed by 30 minutes at 50°C and reaction termination at 85°C for five minutes. 
Residual RNA was eliminated by addition of 1 µl RNAse H for 20 minutes at 37°C. 
3.2.4 Genetic Association Study 
 Genes surrounding the linkage peaks on chromosomes 4 and 19 were functionally 
prioritized based on GO45 and KEGG46 annotations and by using expression data from a 
previously described mRNA expression profiling of AAA and control abdominal aortic tissues48. 
SNPs from the regions in and surrounding the candidate genes were tested for evidence of 
association in order to determine which, if any, to evaluate by gene sequencing. Provided 
sufficient LD between the marker SNP and the risk allele, power calculations using the Genetic 
Power Calculator223 (http://pngu.mgh.harvard.edu/~purcell/gpc/) show sufficient power to detect 
association (Table 3). SNPs were genotyped using the Illumina GoldenGate assay224 and the 
call rate of each SNP was evaluated using the Gencall Software (version 6.1.3.28) from 
Illumina. Deviation from Hardy-Weinberg equilibrium (HWE) was tested using an exact test225 as 
implemented in Haploview226. Allelic association was tested using Chi-squared-test with one 
degree of freedom (DF). To assess the potential for population stratification, HWE and allelic 
association were also tested separately in the Belgian and Canadian subpopulations. Logistic 
regression using Wald and likelihood ratio test (LRT) statistics as implemented in the ASSOC 
program in Statistical Analysis for Genetic Epidemiology (SAGE) software was performed as an 
additional test of association. Haplotype association was analyzed using a score test227 
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implemented using the haplo.score function in the package haplo.stats using the R statistical 
package228. In genes with evidence of association, the LD structure was examined using LD 
plots generated in HaploView software using SNP genotype data obtained from the HapMap229 
CEU (Caucasian) population. 
3.2.5 Sequencing of Functional Positional Candidate Genes 
 Primer pairs specific for the coding sequence of CEBPG, cDNA sequence of PEPD, and 
exonic sequences of CD22 were designed using PrimerQuestSM, a primer design tool based on 
Primer3 software230 available on the Integrated DNA Technologies website 
(http://www.idtdna.com/Scitools/Applications/Primerquest/) (Integrated DNA Technologies, 
Coralville, IA). Predicted melting points, primer hairpins and primer-dimer interactions calculated 
using the SciTools programs in PrimerQuestSM were used in primer selection. One hundred 
microliter volume PCR reactions were set up for sequencing using the following proportions: 10 
µl 10x Buffer II (500 mM potassium chloride and 100 mM Tris-HCl, pH 8.3) (Applied Biosystems 
Inc, Foster City, CA), 25 mM MgCl2 to desired final concentration, 0.8 µl of 25 µM 
deoxynucleoside triphosphates (dNTP), 1.67 µl each of forward and reverse primers diluted to 
10 µM, either 10 µl amplified genomic DNA or 5 µl cDNA, 0.5 µl (2.5 units) of AmpliTaq Gold 
enzyme (Applied Biosystems), and nuclease-free water to the final volume of 100 µl. Reactions 
were prepared on ice and kept chilled until immediate transfer to a thermal cycler heated to 
>90°C. A standard program of 94°C for 10 minutes, followed by 40 cycles of denaturation 
(94°C), annealing (variable) and elongation (72°C), and 3-minute incubation at 72°C was used. 
Detailed cycle times and annealing temperatures are found in Table 6. 
 PCR products were diluted with a glycerol-bromophenol blue loading buffer and loaded 
onto Tris-borate ethylenediaminetetraacetic acid (TBE) agarose gels. Lambda DNA-BstE II 
Digest or 100 bp ladder from New England Biolabs (Ipswich, MA) were used to assess product 
molecular weight depending upon predicted product size. PCR products with single clear bands  
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(Figure 3) of the correct molecular weight were purified for DNA sequencing using Montage™ 
PCR purification columns (Millipore, Billerica, MA). 
 DNA sequencing was performed using the Sanger method231 on purified PCR products 
at the Applied Genomics Technology Center (AGTC) at Wayne State University. Samples and 
primers (Table 7) were diluted according to AGTC instructions. Polymorphisms were identified 
by alignment of sequences using BioX software (available at 
https://www.lagercrantz.name/projects/biox) and manual examination of the sequence plots. 
3.2.6 Functional Analysis of Sequence Variants 
 To assess the potential function of identified sequence variants, in silico functional 
analyses were carried. The freely available web program SIFT232 (Sorting Intolerant from 
Tolerant) was used to predict the structural effects of non-synonymous substitutions. NetPhos233 
was used to predict the creation or destruction of phosphorylation sites. To assess the potential 
effect of 3’ untranslated region (UTR) sequence variants on microRNA binding, predicted 
microRNA binding sites were obtained from the MicroCosm Targets Database234,235 
(http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/). 
3.3 Microarray Expression Profiling 
3.3.1 Baboon Tissue Samples for mRNA Expression Profiling 
 Aortas from adult baboons (Papio hamadryas anubis) (n = 3) were obtained at necropsy 
from animals at the Southwest National Primate Research Center, San Antonio, Texas (Table 
8). The aortas were divided into 10-12 segments, placed in RNAlater solution (Ambion Inc., 
Austin, Texas) and shipped to Wayne State University. Upon arrival, samples were dissected 
and, in order to ensure comparability between individuals, aortic sections were designated 
numbers 1-12 using the aortic arch, renal arteries and iliac bifurcation as landmarks (Figure 4). 
Sections from two baboons were also placed in 10% buffered formalin solution for fixation and 
paraffin embedding. 
3.3.2 RNA Isolation and Quality Control 
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 Total RNA isolation was performed by extraction with guanidinium isothiocyanate and 
centrifugation through a cesium chloride gradient236. Aortic tissue was stripped of adventitia, 
minced using a scalpel in a Petri dish (Figure 5) and then homogenized with a rotor-stator 
homogenizer (PRO Scientific Inc., Oxford, CT) in the presence of 4 M guanidinium 
isothiocyanate, 0.1 M mercaptoethanol, 0.5% sarkosyl in 5 mM sodium citrate (pH 7). Solid 
cesium chloride was added to the samples (final concentration 2.16 M), which were then 
layered onto a cushion of 5.7 M cesium chloride in 0.1 M ethylenediaminetetraacetic acid 
(EDTA). The samples were centrifuged in an ultracentrifuge using a Ti 60.4 rotor (Beckman 
Coulter, Inc., Fullerton, CA) at 41,000 rpm for 18 hours at 20°C. RNA pellets were extracted with 
chloroform:isoamyl alcohol and the RNA precipitated in ethanol with glycogen as a carrier. The 
RNA was resuspended in RNA Storage Solution (Ambion Inc., Austin, TX) containing RNasin® 
(Promega Corp, Madison, WI). 
 In order to assess the quality of RNA used for expression profiling, the concentration and 
RNA integrity of each sample was assessed. RNA concentration was measured using a 
NanoDrop spectrophotometer (Nanodrop products, Wilmington, DE). An independent measure 
of concentration and RNA integrity was obtained using separation by capillary electrophoresis in 
an Agilent BioAnalyzer (Agilent Technologies, Inc. Palo Alto, CA). The RNA integrity number 
(RIN), which measures RNA quality by evaluating ratio of the 28S ribosomal RNA (rRNA) and 
18S rRNA, was determined for each sample in order to ensure sufficient quality for analysis with 
Illumina arrays. RNA quality information is summarized in Table 8. 
3.3.3 Microarray Analysis 
 Following the protocol from Illumina, 500 ng of total RNA (based on Nanodrop 
measurement) was reverse transcribed and 1.5 µg of cRNA was hybridized to either Sentrix 
Human WG-6 version 1 (n = 1) or HumanRef-8 version 2 microarrays (n = 2). The HumanRef-8 
contains 22,184 probes for NCBI RefSeq genes and the Sentrix Human WG-6 contains 47,296 
probes for both RefSeq genes and predicted genes from the UniGene database. Detection of 
  
46 
genes was assessed in Illumina GenomeStudio (formerly BeadStudio) software. Each array 
contains ~30 replicates for each probe sequence; comparison of the distribution of fluorescence 
signals from a probe of interest with the distribution obtained from negative control probes 
allows for a “Detection Score” (1 - detection p-value) to be calculated. Probes with a detection 
score of “0.99” in at least one sample were considered detected for further analysis. 
 Quality control (QC) measures were undertaken to ensure microarray performance. 
Systematic bias was analyzed by examination of raw expression data histograms (data not 
shown) and principle components analysis (PCA) (Figure 6). Additionally, to ensure that the 
Illumina probe sequences directed against a single validated gene, Basic Local Alignment 
Search Tool (BLAST) analysis was performed on each sequence, yielding 21,506 and 20,518 
probes from the Sentrix Human WG-6 and HumanRef-8 platforms, respectively. Probes were 
assigned updated accession numbers and aligned to exons using Perl scripts. Due to probe 
sequence changes made between array versions 1 and 2, probes were mapped between 
platforms using probe sequence, accession number, and exon as criteria. 
 In order to identify genes with relative increases or decreases in expression along the 
length of the aorta, linear regression was performed using the R statistical package. Confidence 
intervals (CI) (99%) were constructed for the calculated slope and those probes with a CI not 
crossing zero were considered to have increasing or decreasing expression. 
3.4 Protein Analyses 
3.4.1 Tissue Samples Used in Protein Expression Studies 
 Control non-aneurysmal aortas (n = 24) were obtained post-mortem at autopsy from the 
local medical examiner in Detroit, Michigan (Table 9). Exclusion criteria were known malignancy 
or systemic infection. Tissue was dissected and transported to Wayne State University in chilled 
saline. The adventitial layer was stripped and the tissue dissected into pieces for protein 
analyses. Dissected samples were fixed in 10% buffered formalin, embedded in Tissue Tek® 
Optimal Cutting Temperature (O.C.T.) media (Sakura-Finetek USA, Inc., Torrance, CA) using  
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plastic cryomolds and frozen over dry ice, or flash-frozen in liquid nitrogen. Formalin-fixed 
samples were embedded in paraffin molds for sectioning after at least 24-hours fixation. Flash-
frozen and OCT-embedded tissues were stored at -80°C until further use. 
 AAA tissue was trimmed from the aneurysmal sac as part of elective surgical repair by 
vascular surgeons (Table 10). Tissue samples were removed solely for the purpose of graft 
placement and would otherwise be discarded. Samples were fixed in formalin solution and then 
embedded in paraffin molds. 
3.4.2 Preparation of Protein Homogenates 
 Between 200 and 400 mg of flash-frozen aortic tissue was weighed in polypropylene 
tubes chilled to -80°C. Three ml of 4°C homogenization buffer consisting of 50 mM 
tris(hydroxymethyl)aminomethane (Tris), pH 7.4, 100 mM sodium chloride, 5 mM EDTA, 5 mM 
ethylene glycol tetraacetic acid, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1x 
Mammalian Protease Inhibitor Cocktail (Catalog Number P8340, Sigma-Aldrich, St. Louis, MO) 
was added to each tube immediately prior to homogenization. Additionally, either 1x HALT 
Phosphatase Inhibitor (Fisher Scientific, Pittsburgh, PA) or Phosphatase Inhibitor Cocktail II 
(Sigma-Aldrich, St. Louis, MO) was included in the homogenization buffer formulation for a 
majority of samples. Samples were homogenized in a biosafety cabinet with tubes resting in an 
ice bath using a chilled rotor-stator homogenizer (PRO Scientific Inc., Oxford, CT) for 2x10 
seconds. Residual solution was rinsed from the homogenizer using an additional 1 ml of 
homogenization buffer. Homogenized samples were centrifuged at ~15,000 g for at least 10 
minutes, the remaining supernatants were transferred to clean tubes and the pellets discarded.  
 Protein homogenate concentration was determined using the biochinic acid (BCA) assay 
from Pierce following the manufacturer’s instructions (Thermo Fisher Scientific, Inc., Rockford, 
IL).  Homogenates were diluted either 1:2 or 1:6 in tris-buffered sodium chloride (TBS), pH 7.4.  
Fifty microliters of diluted sample were added to 1 ml of BCA working reagent and incubated at 
37°C for 30 minutes. A standard curve was prepared according to the manufacturer’s 
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instructions using bovine serum albumin (BSA). Samples were transferred to 1 ml disposable 
cuvettes and absorbance at 562 nm was read using a BioPhotometer spectrophotometer 
(Eppendorf North America, Hauppauge, NY). Sample concentration was determined by 
averaging the concentrations determined by 1:2 and 1:6 dilutions. 
 To check for protein degradation, samples were electrophoresed under denaturing 
conditions on polyacrylamide gels. Samples were diluted to a concentration 0.25 µg/µl in a 
solution of 62.5 mM Tris, pH 6.8, 10% glycerol, 4.1% SDS, 0.1 M dithiothreitol (DTT) and 
0.0005% bromophenol blue. Twenty-microliters of diluted samples were denatured at 100°C for 
5 minutes and loaded onto precast 12% polyacrylamide gels (8.6 x 6.8 cm) from Bio-Rad (Bio-
Rad Laboratories, Hercules, CA). Ten microliters of Novex® Sharp Prestained Protein Standard 
was loaded to one lane (Invitrogen Corporation, Carlsbad, CA). Gels were electrophoresed at 
29 volts/cm in a Bio-Rad electrophoresis cell for approximately 35 minutes. Gels were then fixed 
and stained using a Rapid Coomassie protocol237. Gels were fixed for 30 minutes in 25% 
isopropanol, 10% acetic acid solution followed by staining for at least 2 hours in 0.006% 
Coomassie brilliant blue 250, 10% acetic acid solution. Finally, gels were destained in 10% 
acetic acid and examined for protein degradation (Figure 7). Following assessment of protein 
concentration and integrity, homogenates were aliquotted into 1.5 ml microcentrifuge tubes and 
placed at -20°C for use in western blotting or at -80°C for long-term storage. 
3.4.3 Western blotting 
 Samples were diluted in a solution 58.3 mM Tris, pH 6.8, 5% glycerol, 1.71% SDS, 0.1 
M DTT, and 0.0002% bromophenol blue and denatured for 5 minutes at 100°C. Dilutions were 
made so that antibody dependent amounts of protein (20 µg for HOXA4 and ACTB; 0.5 µg for 
ACTA2) would be present in a 30 µl load. Samples were loaded onto precast 4-15% gradient 
polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA). Five microliters of Novex® Sharp 
Prestained Protein Standard were loaded into one lane. Samples were electrophoresed for 
approximately 35 minutes at 200 volts in a Bio-Rad electrophoresis cell.  Gels were allowed to  
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equilibrate in chilled transfer buffer consisting of 20% methanol, 0.19 M glycine, and 25 mM Tris 
for 15 minutes. Proteins were then transferred to nitrocellulose membranes in chilled transfer 
buffer in a Bio-Rad Mini Trans-Blot Cell (Bio-Rad Laboratories, Hercules, California) at 100 volts 
for 1 hour. After protein transfer, blots were fixed at room temperature for 15 minutes in 25% 
isopropanol, 10% acetic acid, rinsed briefly with 0.1 M Tris, pH 7.5, 0.154 M sodium chloride 
with 0.1% Tween 20 (TBS-Tween or TBST) and blocked for 45 minutes at room temperature in 
5% skim milk in TBST. Blots were then transferred to heat-sealable bags and incubated 
overnight at 4°C with primary antibody diluted in blocking solution. Primary antibodies are 
described in Table 11. Following incubation, blots were washed three times for 10 minutes in 
TBST and incubated for 30 minutes at room temperature followed by 30 minutes at 4°C with 
HRP-conjugated IgG preabsorbed species-specific secondary antibody (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, product number sc-2054 and GE Healthcare Biosciences, 
Piscataway, NJ, product number NXA931) diluted to 1:25,000 in TBST containing 4% serum of 
the secondary antibody species. 
 Following a final washing in TBST, blots were visualized using Pierce SuperSignal West 
Pico enhanced chemiluminescent substrate according to manufacturer instructions Blot 
visualization was done using a Bio-Rad ChemiDoc Imaging system. Autoradiography film 
exposures were also obtained for each blot using either Kodak X-OMAT LS (Eastman Kodak 
Company, Rochester, NY) or Genemate Blue Lite (ISC Bioexpress, Kaysville, UT) film. 
3.4.4 Blot Quantification and Statistical Analysis 
 Quantification of blot density was done using Quantity One® software from Bio-Rad. An 
intensity-per-area value was obtained for each sample band as well as for a control band loaded 
on all blots. Band intensities were adjusted between blots using control band intensities. 
Intensity values adjusted for expression of either smooth muscle actin or beta actin were then 
calculated. Actin-adjusted band intensity values were input into the R statistical package. A 
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Wilcoxon signed rank test was used as a test statistic to compare the intensity values of protein 
bands from thoracic and abdominal aortic wall samples. 
3.4.5 Immunohistochemistry 
 Immunohistochemistry of O.C.T-embedded frozen tissue (Table 9) was performed using 
the VECTASTAIN Elite Avidin:Biotinylated enzyme Complex (ABC) Kit (Vectorlabs, Burlingame, 
CA). Air-dried slides containing eight-micrometer sections were fixed in methanol containing 3% 
hydrogen peroxide to quench endogenous peroxidases and then blocked with serum for 20 
minutes. Treatment with primary antibody, secondary antibody, ABC reagent, and 
diaminobenzadine substrate were performed following manufacturer instructions. Each 
treatment was preceded by a 10 minute PBS wash. Immunostained slides were counterstained 
with hematoxylin and mounted with a coverslip. The primary antibodies used are described in 
Table 11. 
 In some instances, immunostaining was carried out using 5 µm sections of formalin-
fixed, paraffin-embedded (FFPE) aortic tissue (Tables 9 and 10). Sections of human tonsil 
(CD22), human kidney (PEPD) or tissue array containing nine human tissues including kidney 
clear cell carcinoma, malignant melanoma and breast tissue (HOXA4) were used as positive 
controls. Sections were deparaffinized in a dry oven, rehydrated using sequential rinses in 
Histoclear xylene substitute (National Diagnostics U.S.A., Atlanta, GA), 100% ethanol, 95% 
ethanol and water. Antigen retrieval was performed by microwave-treatment of slides. 
Endogenous peroxidase was blocked by placing slides in 3% methanol/peroxide block solution 
for 10 min. The slides were incubated with primary antibody or with serum derived from an 
unimmunized animal of the same species as the primary antibody as a negative control using 
an automatic immunostainer (Autostainer, DAKO, Carpinteria, CA). A secondary antibody with 
avidin-biotin peroxidase amplification from DAKO was used and the signal detected using 
diaminobenzidine as a chromogen. Images were obtained using either a Leica DM4000B (Leica 
Microsystems, Inc., Bannockburn, IL) or Nikon (Nikon Instruments Inc., Melville, NY) 
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microscope using objectives ranging from 4x to 40x. Images were digitally captured with either 
Leica Imaging Suite or Nikon ACT-1 software. Exposure settings for Leica microscope were 
preset238, and for the Nikon microscope were set to 1/300, 1/200, 100 and 1/25 second for the 
4x, 10x, 20x and 40x objectives, respectively. 
3.4.6 Cell Culture and Immunofluorescence 
 Human aortic smooth muscle (catalog number 6110 from ScienCell Research 
Laboratories; and catalog number CRL-1999 from American Type Culture Collection, 
Manassas, VA) and endothelial cells (catalog number 6100 from ScienCell Research 
Laboratories, Carlsbad, CA; and catalog number C-12271 from PromoCell, Heidelberg, 
Germany) were grown on 2-well Permanox chamber slides (Lab-Tek, Thermo Fisher Scientific, 
Rochester, NY). Cells were fixed with 3% paraformaldehyde and permeabilized with 0.05% 
Triton X-100 in PBS, and then incubated with rhodamine-phalloidin (Molecular Probes, 
Invitrogen Corporation, Carlsbad, CA) at 1:100 dilution, and anti-HOXA4 with 1:200 dilution 
(ab26097, Abcam Inc., Cambridge, MA), followed by incubation with fluorescein-conjugated 
affinity-purified donkey anti-rabbit IgG (1:100 dilution in BLOTTO; Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA). The stained cells were examined using a Zeiss Observer 
Z1 inverted light microscope equipped for epifluorescence. 
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4.1 Identification of Potential Risk Alleles in Functional Positional Candidate Genes 
4.1.1 Selection of Functional Candidate Genes 
 The AAA1 and AAA2 linkage intervals together contain over 100 genes. Since it would 
be prohibitively expensive to conduct deep sequencing on each of these genes to identify 
potential risk variants, functional positional candidate genes were identified using several 
criteria. Gene ontology categories and KEGG pathway membership for each gene in the region 
of each linkage peak were examined and ten genes were identified with annotated functions 
directly relevant to AAA pathogenesis (Table 12). Nine of these genes were selected based 
upon an annotated function in the immune system, which was considered relevant to AAA given 
the evidence for AAA as an immune-mediated disease. An additional functional candidate, 
peptidase D (PEPD), was chosen based upon its role in collagen metabolism. 
 Gene expression for each candidate was assessed using microarray expression profiles 
of AAA and control aortic tissue. The expression data were previously generated in our 
laboratory and the study design has been described in detail48. Utilizing expression data in 
functional prioritization has been described in the literature239,240 and by our laboratory44, but 
since all of the functional candidates identified by annotation were expressed in either AAA or 
control abdominal aorta, none were excluded by this criterion. It was noted, however, that four 
of these genes, CEBPA, NFKBID, HCST and TYROBP, were significantly upregulated in AAA 
tissue and that an additional gene, CD22, was expressed only in AAA tissue. 
4.1.2 Candidate Gene Association Study 
 Sixty-six SNPs were genotyped in or around the ten functional candidate genes found 
within the AAA1 and AAA2 linkage loci. Eleven SNPs were excluded from further analysis 
based upon low genotype call rates. SNPs were also tested for evidence of deviation from 
HWE. As HWE disequilibrium can result from underlying biases, such as population structure, or 
from genetic association, HWE was assessed in the two major populations studied, Belgian and 
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Canadian, as well as in conjunction with evidence of association. Four SNPs showed deviation 
from HWE in the absence of evidence of association, and were excluded from further analysis. 
 Using an allelic  χ2 test of association, eight SNPs in three genes, CD22 (2 SNPs), 
PEPD (5 SNPs), and HAMP (1 SNP), were identified as being nominally associated with AAA (p 
< 0.05). When tested for genotypic association using logistic regression, six of these SNPs were 
nominally associated, two were not associated and an additional SNP in GPI was identified. 
Although not significantly associated, SNPs in NFKBID and IL15 did approach nominal 
significance (p < 0.10) by this test. Since there were multiple associated SNPs in PEPD, the LD 
structure of the genotyped SNPs was examined using an LD plot of genotype data from the 
HapMap project CEU Caucasian population (Figure 8). Both the genotyped SNPs and additional 
validated SNPs in the region of CD22 were also examined with an LD plot to examine haplotype 
structure (Figure 9). 
 In order to identify population-specific effects, allelic association was evaluated in the 
Canadian and Belgian subpopulations separately. For a majority of the SNPs identified above, 
evidence of association was stronger in the Canadian subpopulation. Four SNPs (rs756796, 
rs889140, rs7248389, and rs7251432) were nominally associated in the Canadian 
subpopulation alone, but only one of these (rs7248389) showed evidence of association in the 
Belgian subpopulation. It is notable that for the two most significantly associated SNPs in PEPD, 
each was either nominally associated or approaching nominal association in both 
subpopulations. Additionally, for each of the two associated SNPs in CD22, it appeared that 
association results were driven by a different subpopulation. Finally, two associated SNPs 
located in PEPD (rs889140 and rs7248389) did show deviation from HWE driven by the Belgian 
controls, but were not excluded due to evidence of association in the Canadian subpopulation. 
All nominally associated SNPs and their p-values for the different tests are summarized in Table 
13. 
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 Haplotypic tests of association were also performed on SNPs in CD22 and PEPD. Using 
a sliding window of five consecutive SNPs, nominally significant haplotypic association (p = 
0.0026) was identified in the region of PEPD at the SNPs rs10500265-rs6510383-rs7248389-
rs7250833-rs2241380. Nominally significant haplotypic association (p = 0.0065) was also 
identified in two SNPs in CD22 (rs756796-rs2267574). 
4.1.3 DNA Sequencing of Exons in Candidate Genes with Putative Association 
 Sequence analysis is a commonly employed method to identify novel mutations in 
genomic regions with evidence of genetic linkage or association. Three genes, CD22, CEBPG, 
and PEPD, were chosen for DNA sequencing based upon several criteria, including functional 
plausibility, evidence of association and, in the case of CD22, expression in AAA tissue only. No 
significant SNPs were detected within CEBPG, but it was chosen for sequencing since it is in 
close proximity to PEPD and could plausibly contribute to the association signal detected in that 
gene. CD22 was also considered an intriguing candidate gene since it is only expressed in AAA 
tissue. Protein expression of CD22 and PEPD in the aorta was confirmed by 
immunohistochemical staining of paraffin-embedded tissue sections of AAA and control 
abdominal aorta (Figure 10).  
 Exons were sequenced from each gene covering a minimum of the protein coding region 
of each gene since the functional changes associated with exon sequence changes are often 
easier to predict than with intronic sequences. Furthermore, the number of sequencing reactions 
necessary to cover the large intronic regions of CD22 and PEPD was cost-prohibitive. 
  The protein-coding region of CEPBG was sequenced from the genomic DNA of 22 AAA 
cases, 11 familial and 11 sporadic, and two controls. CEBPG does have a large 3’ UTR that we 
chose not to sequence based upon the relatively weak evidence for association within the gene. 
No sequence variants were identified within the regions sequenced and therefore no further 
analysis was pursued with this gene 
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 PEPD contains 15 small exons that are spaced over a large genomic distance, so we 
opted to sequence cDNA since the spliced transcript could be covered in only three PCR 
reactions. Seven sequence variants were identified in PEPD from AAA cases and one control 
(Tables 14 and 15; Figure 11A). Three of the sequence variants identified were novel, in that 
they were not in either the NCBI SNP or Celera databases. Two SNPs coded for non-
synonymous amino acid changes: rs17570, which results in a leucine to phenylalanine 
substitution at amino acid for 435, and a novel variant resulting in an alanine to threonine 
substitution at amino acid 432. 
 Although also consisting of 15 exons, CD22 was sequenced from genomic DNA due to 
the larger transcript size and closer exon spacing that allowed for coverage of multiple exons 
with a single reaction. A total of 20 sequence variants were identified, including five novel 
variants (Tables 16 and 17; Figure 11B). Five variants were in the protein-coding region, 
including two coding for non-synonymous amino acid substitutions, and six were found within 
the 3’ UTR. 
4.1.4 Predicted Functional Changes 
 Several in silico analyses were used to predict whether any of the observed sequence 
changes might alter protein function or regulation of gene expression. To assess the potential 
effect of non-synonymous amino acid substitutions, each sequence variant was analyzed with 
the SIFT web application, which predicts whether amino acid changes that will not be tolerated. 
SIFT predicted that all four amino acid substitutions coded by the sequence variants that we 
identified in CD22 and PEPD would be tolerated. Structural modeling of PEPD demonstrated 
that the identified amino acid substitutions A432T and L435F, resided in close proximity in a 
region that appeared to tolerate structural changes (Figure 12) 
 The 3’ UTR of many genes acts as a binding site for microRNAs (miRNAs) in post-
transcriptional gene regulation241. In order to see if any of the sequence variants identified in the 
3’ UTR of CD22 might interrupt miRNA binding, predicted miRNA binding sites were obtained 
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from MicroCosm database hosted by EMBL-EBI. Binding site predictions for four miRNAs did 
overlap with two sequence variants (Figure 13). Only one binding site prediction had a perfect 
complementarity in the miRNA seed region (base pairs 2-7) and potential base pairing was not 
altered by the sequence change. One SNP (rs73031792) was located in the seed region of two 
predicted binding sites, but since neither prediction had perfect seed region complementarity, 
they were not pursued further. 
4.2 Regional Gene Expression in the Aorta 
4.2.1 Whole-Genome Expression Profiling of Full-Length Baboon Aortas 
 To identify novel candidate genes with spatial expression changes reflective of aortic 
heterogeneity, whole genome expression profiling was undertaken using tissue from the entire 
descending aorta. As no full-length human aortas were available at the time of analysis, aortas 
from baboons (Papio hamadryas anubis) were used. The baboon has been successfully used 
as a model for vascular disease242 and high quality samples could be obtained immediately 
upon necropsy. Since no baboon-specific microarray platform was available at the time of 
analysis, it was necessary to use human microarray platform. Previous reports have also 
successfully used human microarrays to study primate gene expression243,244 and humans and 
baboons have an ~96% homology in DNA sequence, so we were confident that we would have 
sufficient genomic coverage to identify genes for further study. It is possible, however, that even 
a single base pair change complementary to a microarray probe will lead to decreased binding 
so an increase in false negatives was predicted. Illumina BeadArrays were selected for their 
comprehensive genomic coverage, previous successful use by the laboratory48, and ability to 
easily assess expression of a gene through calculation of the detection score based on 
accepted signal detection theory.  
 Microarray analysis of the baboon tissue was conducted in two phases. An initial 
microarray experiment was performed using Illumina Sentrix Human WG-6 arrays to assess the 
feasibility of identifying genes with spatial expression patterns. Aortic samples from two 
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additional baboons were later analyzed using Illumina HumanRef8 arrays. Since Illumina 
updated its probesets between experiments, the two platforms were initially analyzed 
separately. Both platforms performed well with respect to gene expression from the baboon. A 
total of 8,748 probes were detected on the Sentrix Human WG-6 arrays, with a mean of 6,826 
per aortic segment. On the HumanRef-8 arrays, 9,403 and 8,725 probes were detected for the 
two baboons, with means of 7,428 and 7,220, respectively. This expression compared favorably 
with the human expression. Comparing expression in baboon and human abdominal aorta 
probed for using the Sentrix Human WG-6 platform, the baboon sample had 7,384 detected 
probes compared with 12,881 probes detected in human aortas (mean = 10,218), reflecting the 
expected increase in false negatives from using baboon samples on a human platform. 
 To identify genes with potential relevance to the regional nature of AAA, linear 
regression analysis was carried out on the baboon data. The regional nature of aortic 
aneurysms would suggest that genes with well-defined differences between abdominal and 
thoracic aorta would be most informative. Nevertheless, if the true expression either increases 
or decreases monotonically along the length of the aorta, linear regression will identify most of 
the genes with these well-defined differences. Due to the differences between Illumina array 
platforms, linear regression was performed separately for each platform, identifying 832 
significant probes (99% CIs of the regression slope did not cross zero) in the baboon analyzed 
on Sentrix Human WG-6 arrays (Baboon 1) and 86 significant probes from the combined data of 
the baboons analyzed using the HumanRef-8 arrays (Baboons 2 and 3). Combining these data 
identified 23 genes that showed lengthwise increase or decrease in expression in samples 
taken from along the aorta that was consistent between both platforms (Table 18). Genes 
showing the steepest slopes included transforming growth factor, beta-induced, 68 kDa 
(TGFBI), allograft inflammatory factor 1-like (AIF1L), superoxide dismutase 1, soluble (SOD1) 
and deafness, autosomal dominant 5 (DFNA5). Interestingly, three of the 23 genes belonged to 
the homeobox (HOX) family of transcription factors (HOXA2, HOXA9, and HOXC6). Analysis of 
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genes that were detected or probed for on only one platform identified 118 additional genes on 
the WG-6 platform and 25 on the HumanRef-8 platform (data not shown), including two and 
three additional HOX genes, respectively (HOXA10, HOXD8, HOXA4, HOXC8, and HOXC9). 
Based upon these findings, expression of all 38 HOX genes was examined further. In addition to 
the eight HOX genes identified by regression analysis, manual examination of expression 
patterns identified HOXA5, HOXA7, HOXB4, HOXB7, and HOXC10 as having potential 
expression trends (Figure 14). 
4.2.2 HOX Gene Expression in AAA 
 Based upon our observation that the HOX genes exhibit regional expression changes, 
we hypothesized that HOX gene expression might be altered in AAA. A previously performed 
microarray-based comparison of mRNA expression levels in AAA and control abdominal aortic 
tissues using the Sentrix Human WG-6 platform demonstrated expression of 17 HOX genes in 
human abdominal aortic control tissue48, all of which except HOXA4 were detectable in baboon 
abdominal aorta using the Sentrix WG-6 platform. An additional HOX gene, HOXA11, was 
expressed in AAA tissue, but all 17 others had lower expression in AAA tissue, including ten 
that were significantly decreased after correction for multiple testing (Figure 15). 
4.2.3 HOXA4 Protein Expression in Human Aorta 
 Examination of the combined data on spatial and disease-related HOX gene expression 
changes identified a subset of four genes, HOXA2, HOXA4, HOXC6 and HOXD8, which 
exhibited both. As it was the most significantly decreased HOX gene in AAA tissue, HOXA4 was 
chosen for further analysis. In order to confirm that HOXA4 is translated into protein and is 
therefore relevant to vascular function and to offer morphological insight into expression of the 
gene, immunohistochemical staining of aortic tissue was conducted using an antibody specific 
for HOXA4. This antibody binds to HOXA4 on western blots as demonstrated by siRNA 
knockdown245, but has not been tested for use in immunohistochemistry. Initial testing using a 
tissue array showed staining of renal clear cell carcinoma, breast tissue and melanoma (data 
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not shown). Negative control staining using a non-immune rabbit serum exhibited some light, 
diffuse staining but with most areas devoid of stain (data not shown). 
 Since formalin fixation of tissue in conventional immunohistochemistry can result in 
epitope crosslinking, immunohistochemistry of frozen sections was initially carried out. Using 
cryosections of paired human thoracic and abdominal aortic tissue embedded in OCT media (n 
= 6 pairs), staining was observed in the nuclei and perinuclear regions of several cell types 
through all three layers of the aorta (Figure 16A). Intimal staining of endothelial cells and medial 
staining of SMCs were both observed, with the outer half of the media staining more intensely in 
several cases. Sparse staining was observed in the adventitia, especially surrounding 
adventitial vessels. As preparation of the frozen sections lead to some disruption of cell 
morphology, immunohistochemistry using FFPE tissue samples was also tested. Similar 
staining patterns were observed with primarily nuclear and perinuclear staining (Figure 16A-B). 
Several tissue sections also exhibited a more diffuse, punctate staining pattern in both frozen 
and FFPE sections. Staining did not differ qualitatively between thoracic and abdominal aorta, 
with staining observed in similar cell types and vessel layers (Figure 16 D-E). 
 Closer examination of the punctate staining pattern showed that it was only present in 
tissues from adult donors and was particularly strong in elderly donor tissue (age > 50). In 
contrast, tissue from the three adolescent donors exhibited a more localized staining pattern 
around the nuclei. These age-related differences were present in both frozen and FFPE 
sections. Consultation with a pathologist confirmed that the nuclear staining in the younger 
samples was most likely specific, but that the diffuse staining in the older individuals was a 
possible artifact due to reagent reactions to calcium deposits in the tissue. Potential age-related 
differences were not quantitated, however, due to an insufficient number of adolescent samples 
available for comparison.  
 To confirm the HOXA4 expression patterns observed in the baboon aortas, HOXA4 
protein expression was assessed quantitatively by western blotting of paired human thoracic 
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and abdominal tissue. In non-aneurysmal aortic tissue, HOXA4 was detected as a single band 
running at ~33 kDa (Figure 18A). At the time of analysis, no full-length recombinant peptide or 
expression lysate was available as a positive control, but the antibody did bind to the 
immunizing peptide, (Figure 18B) and, as noted above, it has shown specificity on western blots 
in siRNA knockdown experiments245. For quantification purposes, beta-actin was used as a 
loading control (Figure 18C). Using 24 paired human thoracic and abdominal aortic tissue 
samples, the beta-actin adjusted HOXA4 expression in the thoracic aorta was significantly 
higher than in the abdominal aorta (p < 0.0001), which was consistent with the expression 
pattern observed in the baboon microarray analysis (Figures 19 and 20A). Since the thoracic 
aorta has a higher smooth muscle content than the abdominal aorta, smooth muscle alpha actin 
levels were also investigated to determine whether the difference (Figure 18D) in HOXA4 
expression was a result of differences in SMC density. After correction for alpha-actin content, 
the expression differences between abdominal and thoracic aorta changed slightly but remained 
significantly different (p < 0.001), an indication that SMC density might have a small effect on 
HOXA4 expression but does not account for the main observation of spatial difference in 
HOXA4 levels (Figures 19 and 20B). 
 The effect of age on HOXA4 expression was also investigated using western blot data. 
Regression lines were generated for the human thoracic and abdominal aortic samples that 
identified negative correlation between HOXA4 protein levels and age (Figure 21). 
4.2.4 In Vitro Characterization of HOXA4 Protein 
 In order to further characterize the cellular localization of HOXA4 protein in the vascular 
cells, immunofluorescent staining for HOXA4 was performed using cultured low-passage human 
aortic endothelial cells (HAECs) and human aortic smooth muscle cells (HASMCs). Staining 
was strongest in the perinuclear region, with some evidence of nuclear staining (Figure 22). 
HOXA4 did not colocalize with filamentous actin, which stained using rhodamine-phalloidin. The 
staining pattern observed was similar between the different cell types. 
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CHAPTER 5 – DISCUSSION 
 
5.1 Genetic Association and Sequencing of Functional Positional Candidate Genes 
5.1.1 Identification of Candidate Genes in the AAA1 and AAA2 Linkage Intervals 
 This study utilized genetic association methods and exon sequencing to identify 
sequence variants contributing to AAA risk. Strong evidence of linkage exists on chromosomes 
4 and 19 in the AAA1 and AAA2 loci36,37, but there are several hundred genes within these two 
regions combined, necessitating the use of additional methods to identify specific risk genes. To 
do this, we functionally prioritized the genes in the regions surrounding the linkage peaks using 
annotation databases and expression profiling of AAA and non-diseased control abdominal 
aortic tissue. The freely available GO and KEGG databases allowed us to quickly identify ten 
genes with annotated functions relevant to AAA pathogenesis, a number that was deemed more 
manageable for further study. In contrast to previous association studies that have focused 
genes specifically identified in AAA pathogenesis, our approach was not restricted to genes with 
a known function in aneurysms. Rather, each gene we identified needed only to have a 
plausible role in aneurysm etiology or pathogenesis. The genes identified ranged from clearly 
relevant, such as IL15, a cytokine with diverse roles in the immune system including stimulation 
of T-cell proliferation246 to more tangential, such as GPI, which normally functions in glycolysis, 
but has autoantigenic properties247. One limitation of this approach was that poorly or 
unannotated genes may have been missed. Alternative methods such as text-mining of 
abstracts may have yielded a more complete list of functional candidate genes, but would have 
likely been far more time consuming and may not have yielded much additional information. 
 Gene expression was also included as an additional functional criteria to prioritize 
candidate genes44. Although it is acknowledged that there are plausible scenarios where a gene 
that is expressed in a different tissue could alter disease risk, this was deemed less likely for a 
highly regional disease like AAA. Since each of our functional candidate genes was expressed 
  
63 
in either AAA or control abdominal aortic tissue, this criterion was not critical to this study. 
Genes expressed significantly higher or only in AAA tissue, however, were of additional interest 
from a functional standpoint. 
5.1.2 Genetic Association Studies 
 Association testing of the functional positional candidate genes demonstrated nominal 
association in four genes. Despite evidence of linkage, identification of nominally significant 
SNPs was not expected due to the potential for allelic heterogeneity or rare variants. Evidence 
of association in two of the candidate genes, PEPD and CD22, was of considerable interest. 
PEPD and CD22 are particularly strong candidate genes for altering AAA risk, based on gene 
function, association evidence, and gene expression. We have also shown that both genes are 
present as protein in AAA tissue, indicating that they can plausibly affect disease pathogenesis. 
 PEPD, which is also known as prolidase, is an aminodipeptidase that cleaves di- and 
tripeptides with C-terminal proline or hydroxyproline residues. It has a significant role in collagen 
metabolism and dysregulation of its activity has been implicated in several diseases248. Loss of 
PEPD activity from nonsense mutations results in a clinical syndrome of variable expressivity, 
but may include skin lesions, mental retardation, facial malformations and recurring lung 
infections248. Conversely, increased serum activity of PEPD has been associated with diseases 
such as asthma249, CAD250, fatty liver disease251, and erectile dysfunction252. PEPD activity is 
sensitive to doxycycline253, which is intriguing given the therapeutic potential of this drug in AAA. 
 CD22 is a sialic-acid binding protein found on cells of B-cell lineage. It can inhibit signaling 
through the B-cell receptor254, suggesting that impairment of gene function might lead to 
dysregulation of the immune response and either autoimmune disease or increased 
inflammation. Supporting this hypothesis is evidence of a role for CD22 in systemic sclerosis 
(SSc); anti-CD22 autoantibodies contribute to SSc pathogenesis255 and there is evidence of 
association between a SNP in CD22 and SSc256. Cd22 knockout mice, however, display a 
minimal phenotype with no evidence of increased autoimmune disease254. It is still plausible, 
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however, that polymorphisms in CD22 might modulate the immune response in an inflammatory 
disease such as AAA through changes in the amount or function of the gene. 
 Despite the presence of nominally associated SNPs, evidence of association was 
weaker in HAMP and GPI and they were therefore not selected for sequencing. Both genes had 
only one nominally associated SNP in the region of the gene; evidence of association in 
additional SNPs would make a stronger case for possible risk modification in AAA. The currently 
known functions of HAMP and GPI also make them less compelling, although still plausible, 
candidate genes for AAA. As previously mentioned, GPI primarily acts an enzyme in glycolysis 
and gluconeogenesis but has also been described as an autoantigen in rheumatoid arthritis 
(RA)247. This is intriguing given the hypothesis that AAA also has an autoimmune component, 
but a connection between the diseases is not supported by either RA or AAA epidemiology. 
Inflammatory AAA has been associated with autoimmune disease and there are rare cases of 
rheumatoid aortitis257, but there have been no observations concerning phenotypic overlap of 
either sporadic or familial AAA and autoimmune disorders. The primary function of HAMP is in 
iron metabolism, but it also has antimicrobial function in macrophages. Similar to the severe 
phenotype seen with mutation in PEPD, mutations in HAMP result in juvenile hereditary 
hemochromatosis258, suggesting that any risk alleles for AAA would be due to tissue-specific 
alternative splicing or transcription, but not drastically alter normal gene function. 
 It is also possible that our observed association was spurious, the result of population 
stratification or random chance. A recent association study examining SNPs from the 
chromosome 19 linkage interval in the Dutch population did find several nominally associated 
SNPs but none remained significant for multiple testing259. Interestingly, the SNP showing the 
strongest evidence of association resided in CEPBG, which is in agreement with our 
observation of association in the region of CEBPG and PEPD. 
5.1.3 Sequence Analysis of Candidate Genes 
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 Both PEPD and CD22, but not CEBPG, had polymorphic coding regions. 
Polymorphisms that did not result in amino acid substitution or changes to the 3’ UTR were not 
considered further, since their functional effects are hard to predict and therefore, without further 
evidence of association, were not considered worth additional follow-up. Although in silico 
predictions will not predict all of the effects of sequence changes, we did not consider functional 
testing to be warranted unless the specific variants were demonstrated to show further evidence 
by association or clustering within familial cases. After investigation for predicted functional 
consequences, all of the sequence changes identified in the coding regions or 3’ UTR of CD22 
and PEPD appeared to be tolerated. With respect to PEPD, it was not surprising that the 
sequence variants had no predicted deleterious effects, given the phenotypes associated with 
loss of gene function. Rather, it is more likely that a risk allele would result in increased PEPD 
activity or a gain-of-function in vascular tissue. With respect to CD22, although there were no 
predicted functional changes, it is of note that for two pairs of SNPs, rs10406069-rs73031792 
and rs45453699-40529534, the variant alleles were seen in a similar set of samples suggesting 
the presence of two different LD blocks. Furthermore, the rs10406069 A allele and rs45453699 
T allele were present in AAA cases only, whereas the other two SNPs were identified in both 
control cases. Based upon the small sample size, particularly with only two controls analyzed, 
one should not draw conclusions. Given that both of these SNPs are common in the population 
(MAF ~ 0.20), however, they would be appropriate for further association testing. 
5.2 Identification of Regionally Expressed Candidate Genes 
5.2.1 Spatially Expressed Candidate Genes 
 The results of this study provide evidence of specific gene expression differences 
between the descending thoracic and abdominal aorta. Several of these genes are interesting 
functional candidates for further study. For example, both TGFBI, which is an extracellular 
matrix protein that mediates adhesion of cells to collagen through interaction with integrins, and 
AIF1L, which is closely related to the inflammatory signaling molecule AIF1, could plausibly be 
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involved in AAA etiology and pathogenesis. Since several of the HOX transcription factors were 
identified and since regional expression differences are consistent with previous research, we 
chose to focus further study on these genes. 
 Based on current understanding of collinear expression of HOX genes, the expression 
patterns we observed were reasonable. In the thoracic aorta genes from paralogous groups 1-4 
exhibited the highest expression, two of which, HOXA2 and HOXA4, had decreasing expression 
from the thoracic to abdominal aorta. These genes show similar expression in the developing 
lung260,261, so it is possible they may have similar expression patterns in the vasculature. HOXB4 
also appeared to show decreasing expression starting at a point in the descending thoracic 
aorta, but the regression slope was not significantly different from zero. HOXA3, which has been 
observed in the superior regions of the murine aorta209, was not detected in neither microarray 
platform, although this may have been due to human and baboon sequence differences. 
Expression was not also observed in the human samples, suggesting possible microarray probe 
problems for this gene. In the abdominal aorta, genes from the paralogous groups 8-10 showed 
increased expression, which is consistent with the maximal expression of Hoxc11 in mouse 
femoral arteries209. 
 Several of the HOX genes we identified have documented vascular function. HOXA5 
and HOXB5, which showed consistent levels of expression across most of the aorta, act to 
decrease262 and increase262 endothelial cell migration, respectively. HOXA9, which is expressed 
as a novel splice variant in endothelial cells215, has also been implicated in upregulating 
angiogenic response217,263. 
 Discrepancies between microarray platforms in the expressed HOX genes suggest one 
study weakness, namely that we may not have detected expression of HOX genes based on 
either human-baboon sequence differences or problems with the platform used. There was 
significant overlap in HOX genes expressed in human and baboon abdominal aorta using the 
Sentrix WG-6, with HOXA4 being a notable exception. This indicates that inter-species 
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sequence differences were likely a problem for HOXA4 only. Conversely, HOXC8 and HOXC9 
were detected in baboon tissue using the HumanRef8 chip but not in either species using the 
Sentrix WG-6, suggesting that there were poorly performing probes on the Sentrix WG-6. 
5.2.2 Expression of HOX Genes in AAA and Control Tissue 
 Examination of data from an expression profiling experiment comparing human AAA and 
control tissue demonstrated that ten HOX genes were significantly downregulated in AAA. 
There have been several reports of HOX genes being downregulated by inflammatory 
conditions. Sarno and colleagues showed decreased expression of several genes from the 
HOXA cluster upon treatment with interleukin 1ß (IL1B), an inflammatory cytokine that is 
significantly upregulated in AAA tissue264. HOXA9 has also been shown to be responsive to 
TNF stimulation in endothelial cells, where it is transiently involved in upregulation of E-selectin 
(SELE)214,215. Similar to our analysis, a study comparing gene expression in ulcerative colitis, 
another immune-mediated disease, and normal colonic mucosa identified HOXA4 as one of two 
significantly downregulated genes in diseased tissue265. Another microarray expression profiling 
by Seo, et al. also identified several HOX genes, including HOXA4, HOXA5 and HOXC6, as 
being associated with susceptibility to atherosclerosis in the thoracic aorta266. The direction and 
magnitude of expression changes were not described, however, making further interpretation 
difficult. 
 The functional roles of HOX genes in the vasculature also make them appealing 
candidates for further study. Varying roles in regulation of cell proliferation and differentiation 
suggest that the downregulation we have observed might alter cell phenotype in disease. As 
different HOX genes act through different mechanisms and with opposing effects, it will be 
necessary to assess the complement of HOX gene expression at a vascular site in order to fully 
understand their functions. At least two of the genes showing spatial or disease-related 
expression, HOXC8 and HOXA9, can negatively-regulate SPP1, which has been previously 
implicated in AAA pathogenesis. In light of our findings in the association study, coordinated 
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regulation by several HOX genes suggests one possible mechanism for how a gene with 
widespread expression could contribute to a localized phenotype. For example, under 
conditions predisposing to AAA, the complement of HOX genes in the abdominal aorta could 
lead maximal upregulation of a gene such as PEPD. 
5.2.3 HOXA4 Expression in the Aorta 
 Although HOXA4 transcript has been previously described in aortic tissue, no further 
studies, including HOXA4 protein analyses or studies on the role of HOXA4 in AAA, have been 
published so far. Our western blot data demonstrated protein expression of HOXA4 in aortic 
tissue and that it differed significantly between the thoracic and abdominal aorta after correction 
for beta-actin expression, confirming in principle that our observations from the baboon aorta 
microarray study were not simply the result of false positives. Demonstration of protein 
expression is important since overall there is weak correlation between protein and transcript 
levels of the different genes in the human genome. Furthermore, the HOX loci contain 
numerous non-coding RNA transcripts267 that can either overlap with HOX gene sequences or 
potentially post-transcriptionally alter HOX gene levels. 
 Qualitative analysis of HOXA4 protein by immunohistochemistry showed evidence of 
protein expression in all three histological layers with staining observed in the nuclei of several 
cell types, including ECs and SMCs. This was also shown by in vitro staining of cultured 
vascular ECs and SMCs, which demonstrated perinuclear and nuclear localization of HOXA4 
protein. The expression of HOXA4 in both ECs and SMCs is interesting, as Pruett and 
colleagues observed that Hoxa3 is expressed in both cell types in the mouse vasculature, 
whereas Hoxc11 expression was seen in SMCs only. HOXA9 has also been described in both 
endothelium and smooth muscle214,215, indicating that this may be characteristic of the HOXA 
cluster. Our immunohistochemistry data were limited by the presence of aggregate-staining that 
was deemed to be an artifact, most likely a result of calcifications of the aortic wall. Although this 
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artifact did not generally overlap with the specific nuclear staining, it did limit us to qualitative, 
rather than quantitative analysis. 
 Given that SMCs express HOXA4, we were concerned that the expression difference 
between thoracic and abdominal aorta might simply be a result of the anatomical differences in 
smooth muscle content. Adjustment for smooth muscle actin content demonstrated that this was 
not the case, although it is not clear if our observations were a result of a smaller percentage of 
cells expressing HOXA4 or lower per-cell levels of HOXA4. Although quantification was not 
practical due to nature of staining in some aortas, there was some suggestive evidence of an 
increased percentage of nuclei expressing HOXA4 in the thoracic sections of adolescent aortas 
relative to their abdominal sections. This is consistent with a previous observation that subsets 
of cells express Hoxa3 and Hoxc11 in the mouse vasculature209. 
 Our western blot data, and to a limited degree our immunohistochemistry data, 
demonstrated changes in HOXA4 expression with age. A previous study did show that HOX 
gene expression differs between fetal and adult rat vascular smooth muscle cells with Hoxa4 
detectable only in the adult cells268. Our data showed higher protein levels by western blot in 
aortas from young donors, suggesting that HOXA4 may function in vascular growth during 
adolescent development and puberty. Immunohistochemical staining observed primarily in 
nuclei of SMCs in the medial layer of aortas from adolescent cases further supports the 
hypothesis that HOXA4 has an active role in transcriptional regulation. The age-related 
decrease in HOXA4 protein observed by western blot suggests that function of HOXA4 may be 
diminished over time, either due to the aging process or the development of atherosclerosis. 
This correlates with some evidence of qualitative changes by immunohistochemistry. Although 
not quantified due to small sample size, there was a trend towards a decrease in specific 
nuclear staining in the tissues from older donors. While the presence of intense cytoplasmic 
staining also observed in these tissues could represent a real biological effect, it was deemed 
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more likely a result from substrate interaction with calcium deposits normally present in older 
tissues. 
 As our study did not specifically address HOXA4 function, we can only speculate at this 
time as to what its role is in aortic biology and disease. Currently, there have been no 
comprehensive chromatin immunoprecipitation (ChIP) analyses identifying HOXA4 target 
genes. HOXA4 can bind to its own promoter region269 and there is some evidence for HOXA4 
regulating the adjacent HOXA5 gene under certain conditions261,270. An analysis of the tyrosine 
hydroxylase promoter identified a putative HOXA4 binding site, but this was not confirmed by 
ChIP271. Schmeier, et al.272 implicated HOXA4 in the regulation of microRNA genes during 
monocyte differentiation, suggesting a possible mechanism for HOX gene regulation of cell type 
specific effects. Similar to several other HOX genes, dysregulation of HOXA4 expression, either 
by upregulation or downregulation, occurs in malignancies such as leukemias273-275 and ovarian 
carcinoma245 where it may be associated with an altered prognosis. 
 Similar to other HOX genes, HOXA4 does have known function in embryonic patterning. 
Its function in embryogenesis does not, however, appear to be critical, which is not surprising 
given that it is one of four paralogs with predicted functional redundancy. Targeted disruption of 
Hoxa4 results in a relatively mild phenotype; Hoxa4 knockout mice are viable and exhibit only 
some deformations of the cervical spine, including a homeotic transformation of the third 
cervical vertebra resulting in the presence of a process similar to that found in the second 
vertebra suggesting functional redundancy between HOXA4 and other HOX genes276,277. 
Conversely, transgenic mice overexpressing the Hoxa4 gene develop congenital megacolon 
due to abnormalities in the enteric nervous system278.  
 HOXA4 does not appear to be critical to vascular development, with low to undetectable 
expression in developing blood vessels279. Unlike the adjacent HOXA3, which is necessary for 
proper formation of the aortic arch, neither HOXA4 nor its three paralogs appear to be important 
in vascular patterning212,213. In a study by Kirby and colleagues, no detrimental changes were 
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observed in aortic arch formation when all four genes were simultaneously disrupted with 
antisense RNA280. 
 Despite not being critical to vascular patterning, our observations suggest that it 
functions in differentiated vascular tissue, especially during times of vessel growth. One 
possibility is that similar to other HOX genes, HOXA4 helps to regulate vascular cell proliferation 
or differentiation. This is supported by an in vitro comparison of ovarian carcinoma cell lines that 
showed that cells exhibiting higher levels of HOXA4 expression have decreased motility by 
scratch assay245. Another study by the same group also demonstrated that overexpression of 
HOXA4 further decreased cell motility and lead to a corresponding increase in ß1 integrin281. 
siRNA knockdown of HOXA4 did not ablate ß1 integrin expression, however, which is consistent 
with HOX genes having redundant functions. The role of HOXA4 in mediating cell contacts is 
further supported by an increase in basal lamina thickness and collagen in the colonic mucosa 
of Hoxa4 transgenic mice278. With respect to AAA, significant downregulation of ß1 integrin has 
been observed relative to non-diseased aorta149. It is therefore plausible that loss of HOXA4 
function in medial SMCs contributes to adverse phenotypic changes in aneurysms including 
disruption of cell-cell interactions. 
 The regulatory mechanisms of HOXA4 also suggest that HOXA4 may be relevant to 
vascular function and disease. HOXA4 regulation is complex, involving several mechanisms, 
including chromatin remodeling, non-coding RNA, variable 3’ processing, and potentially 
multiple splicing282. It is one of several HOX genes to have a retinoic acid response element 
(RARE) in its promoter, which, when activated in coordination with an AP-2 transcription 
factor283 or by autoregulation269, can upregulate HOXA4 expression. HOXA4 is also TGF-ß 
responsive, with TGF-ß stimulation showing an opposing effect to retinoic acid in developing 
lung tissue261. Both of these regulatory mechanisms are relevant to AAA pathogenesis. Recent 
evidence has shown anti-inflammatory effects of TGF-ß in a mouse model of AAA284. Retinoic 
acid stimulation can decrease SMC proliferation and migration285, as well as increase SMC 
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production of inflammatory signaling molecules such as IL1B286, SERPINE1 (PAI-1)287, and 
adrenomedullin288, all of which have been implicated in AAA. The effects of neither TGF-ß nor 
retinoic acid on HOXA4 expression in adult vascular cell types have been explored, however, 
nor is there currently evidence of HOXA4 regulating any of these genes. Furthermore, as noted 
above, several HOX genes are downregulated after IL1B stimulation, indicating that further work 
is necessary to understand the role of HOXA4 in vascular inflammation. 
 Finally, one important consideration in trying to understand the role of HOXA4 in the 
vasculature is that it should be studied in the context of other HOX genes. Evidence 
demonstrates that HOXA4 is involved in multi-HOX gene regulatory networks. For example, 
Hoxa4 can regulate retinoic acid induced production of Hoxa5 in mice261,270 but cotransfection 
with HOXA1 and HOXA5 decreases activation of the HOXA4 promoter289. Furthermore, 
functional redundancy, both for processes regulated, such as angiogenesis, as well as specific 
target genes, such as SPP1, makes it necessary to assess the mechanisms of several HOX 
genes together. Even in the absence of functional redundancy, multiple HOX genes may still 
contribute to a particular phenotype, as suggested by the differences between white adipocytes, 
which express HOXA4 and HOXD4 and brown adipocytes, which express HOXC4 and 
HOXD4290. 
 Going forward, extensive work will be necessary to characterize the role of HOXA4 in 
the vasculature. The next step will be to establish functional relevance of HOXA4 through either 
in vitro analyses, such as characterization of the effects of HOXA4 overexpression or 
knockdown, or the use of animal models. As little is known about its transcriptional targets, ChIP 
assays to identify target genes of HOXA4 and other HOX genes would be another important 
step in understanding HOXA4 function. 
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CHAPTER 6 – CONCLUSION 
 
 AAA is a multifactorial disease of the aging population with a combination of several 
environmental and genetic risk factors. Studies of late-stage AAA tissue have demonstrated that 
AAA is an immune-mediated disease involving ECM breakdown, loss of SMCs, and 
inflammatory infiltration of the adventitia and outer media. Epidemiological evidence suggests 
that factors including genetic differences, age-related changes to the vasculature, tissue 
damage from smoking, and hormonal factors may also contribute. Yet the molecular 
mechanisms involved in AAA, especially early in the disease, are still not well understood. The 
results described here have identified several functional candidates for better understanding the 
etiology and pathogenesis of this disease. Specifically, we have identified two functional 
candidate genes in the chromosome 19 interval, CD22 and PEPD, that exhibit nominal evidence 
of genetic association in a population of Caucasian individuals and have demonstrated that the 
observed association likely not due to changes in coding sequence. We have also 
demonstrated by microarray expression profiling that there are regional gene expression 
differences in the human aorta and have identified the HOX genes as exhibiting spatial and 
disease-related changes in expression. Further analyses using western blotting and 
immunohistochemical staining of human aortic tissue samples of one of the HOX genes, 
HOXA4, confirmed our microarray results and identified age-related changes in gene 
expression. 
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Appendix A – Tables 
Table 1. Familial prevalence of AAA based on patient interviews. 
Study Patients 
Surveyed (N) 
Patients with 
Positive History (N) 
Familial 
Prevalence (%) 
Norrgård et al. 1984 291 87 16 18.4 
Johansen and Koepsell 1986 292 250 48 19.2 
Powell and Greenhalgh 1987 293 56 20 35.7 
Johnston and Scobie 1988 294 666 41 6.1 
Cole et al. 1989 295  305 34 11.1 
Darling et al. 1989 85 542 82 15.1 
Majumder et al. 1991 76 91 13 14.3 
Verloes et al. 1995 77 313 39 12.5 
Lederle et al. 1997 296 985 91 9.2 
Lawrence et al. 1998 297 86 19 22.1 
Salkowski et al. 1999 298 72 19 26.4 
Rossaak et al. 2001 299 248 48 19.4 
Totals 3701 470  
Combined Prevalence   12.7 
Modified from Kuivaniemi & Tromp, 2000300 with permission from Landes Bioscience. 
 
Table 2. Prevalence of AAA among first-degree family members based on 
ultrasonography screening. 
Study Country Brothers1 (%) Sisters1 (%) Other1 (%) 
Bengtsson et al. 1989 301 Sweden 10/35 (28.6) 3/52 (5.8)  
Collin & Walton 1989 302 UK 4/16 (25.0) 0/15 (0)  
Webster et al. 1991 303 USA 5/24 (20.8) 2/30 (6.7) 7/103 (6.8) 
Adamson et al. 1992 304 UK 5/25 (20.0) 3/28 (10.7)  
Bengtsson et al. 1992 305 Sweden   9/62 (14.5) 
van der Lugt et al. 1992 104 Netherlands 16/56 (28.6) 3/52 (5.8)  
Adams et al. 1993 306 UK 4/23 (17.4) 1/28 (3.6) 6/23 (26.1) 
Moher et al. 1994 307 Canada 9/48 (18.8)   
Fitzgerald et al. 1995 308 Ireland 13/60 (21.7) 2/65 (3.1)  
Larcos et al. 1995 309 Australia   0/52 (0) 
Baird et al. 1995 310 Canada 7/26 (26.9) 3/28 10.7)  
Jaakkola et al. 1996 311 Finland 4/45 (8,9) 1/78 (1.3)  
van der Graaf et al. 1998 
312 
Netherlands 26/210 (12.4)   
Salo et al. 1999 313 Finland   11/238 (4.6) 
Rossaak et al. 2001 299 New Zealand   4/49 (8.2) 
Frydman et al. 2003 314 Australia 64/150 (42.7) 20/126 (15.9)  
Ogata et al. 2005 315 Canada 11/98 (11.2) 4/147 (2.7) 0/31 (0) 
Badger et al. 2007 316 Northern Ireland 8/136 (5.8) 2/122 (1.6( 0/42 (0) 
Total  186/952 (19.5) 44/771 (5.7) 37/638 (5.7) 
1Number of individuals identified with AAA/number of individuals examined by ultrasonography. 
Other refers to relatives other than sisters and brothers of the AAA-patient, or the categories of 
relatives were not specified. Modified from Kuivaniemi & Tromp, 2000300 with permission from 
Landes Bioscience. 
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Table 3. Power calculations for genetic association studies. Table shows number of 
case/control pairs necessary to detect association at 80% power. Numbers were calculated for 
multiple odds ratios assuming either dominant, recessive or additive genetic models. All power 
calculations were performed using the Genetic Power Calculator223 assuming a D’ of 0.99 and a 
prevalence of 2%. 
Dominant Model Recessive Model Additive Model MAF 
RR: 1.5 RR: 1.8 RR: 2 RR: 1.5 RR: 1.8 RR: 2 RR: 1.5 RR: 1.8 RR: 2 
0.10 611 283 201 36,700 14,600 9431 1716 742 507 
0.30 516 259 192 1901 793 529 840 388 276 
0.40 659 340 257 989 425 283 783 373 269 
Abbreviations: MAF, Minor allele frequency; RR, Relative risk 
Used with permission from Kuivaniemi, et al., 2008317. 
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Table 4. Samples used for sequencing of CEBPG and CD22. Genomic DNA was isolated 
from the blood of AAA cases and controls and underwent whole-genome amplification for use in 
PCR amplification. Twenty-four samples were selected for each PCR reaction and were chosen 
to represent familial and sporadic AAA. 
Sample Lab ID1 Pedigree1 Status Origin Sex CEBPG CD22 
1 VD4779 AAA720 Case2 Netherlands M Yes Yes 
2 SARAH AAA004 Case2 USA F Yes Yes 
3 MS2998 AAA183 Case2 Canada F Yes Yes 
4 24381 AAA160 Case2 Canada M Yes Yes 
5 III-5 AAA101 Case2 Canada F Yes Yes 
6 MS4264 AAA223 Case2 Belgium M Yes Yes 
7 MS6747 AAA491 Case2 Canada M Yes Yes 
8 MV0110 AAA702 Case2 Netherlands M Yes Yes 
9 23314 AAA048 Case2 USA M Yes Yes 
10 B21 AAA008 Case2 England M Yes Yes 
11 GP1023 AAA005 Case2 USA F Yes Yes3 
12 A81 AAA007 Case England F Yes Yes 
13 GP4596 AAA104 Case Canada F Yes Yes 
14 23342 AAA116 Case Canada F Yes Yes 
15 23103 AAA121 Case Canada M Yes Yes 
16 23078 AAA118 Case Canada M Yes Yes 
17 MS4194 AAA411 Case Canada M Yes Yes 
18 MS4968 AAA449 Case Canada F Yes Yes 
19 MV0100 AAA701 Case Netherlands M Yes Yes 
20 VD4893 AAA739 Case Netherlands M Yes Yes 
21 AV063 AAA212 Case Belgium M Yes Yes 
22 C7 AAA009 Case England F Yes Yes 
23 GP4692 AAA011 Case USA F  Yes3 
24 GP4421 AAA004 Control USA F Yes Yes3 
25 23312 AAA048 Control USA F  Yes3 
26 23443 AAA124 Control Canada F  Yes3 
27 MS2748 AAA160 Control Canada F  Yes3 
28 23295 AAA132 Control Canada M  Yes3 
29 23287 AAA132 Control Canada M Yes  
1Laboratory specific identification for sample and family 
2Case in chromosome 19 linked family. 
3Sample not used in every sequencing reaction. 
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Table 5. Samples used for sequencing of PEPD. RNA was isolated from skin fibroblasts of 
AAA cases and controls and reverse transcribed to cDNA for use in PCR amplification. 
 
Sample Lab ID1 Status Origin Sex Template 
30 TAGE Case2 Sweden M cDNA 
31 HS11 Case USA M cDNA 
32 GOTOM    cDNA 
33 ZIRIC    cDNA 
34 WC12 Case Canada  cDNA 
35 WC15 Case Canada  cDNA 
37 WC16 Case Canada  cDNA 
38 WC20 Case Canada  cDNA 
39 WC14 Case Canada  cDNA 
40 WC18 Case Canada  cDNA 
41 WC19 Case Canada  cDNA 
42 WC26 Case Canada  cDNA 
43 DODT    cDNA 
44 JOHA Control3   cDNA 
45 WACAR    cDNA 
46 HS02 Case USA F cDNA4 
47 HS03 Case USA M cDNA4 
48 HS07 Case USA M cDNA4 
49 HS09 Case USA M cDNA4 
50 BEJO Case  M cDNA4 
51 HS12 Case USA M cDNA4 
52 HS13 Case USA M cDNA4 
53 GOHN Case USA M cDNA4 
54 GOSE Case USA M cDNA4 
1Laboratory specific identifier 
2Diagnosis of AAA and IA. 
3Patient had osteogenesis imperfecta 
4Sample stored as RNA and reverse transcribed to cDNA. 
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Table 6. PCR primer pairs for CEPBG, PEPD and CD22. 
Reaction Sequence Product Size 
(bp) 
Annealing 
Temp (°C) 
Cycling Times 
(Seconds) 
MgCl (mM) 
CEBPG  F: CGTGGAAACCATTGATCACCCT 640 57 30-30-60 1.5 
Coding R: AGCCTCCAATGGGTCTTTGAGTC     
      
PEPD F: CATGCATTGGCACCCGGAG 569 54 60-45-60 1.5 
cDNA #1 R: CTTGCTGATGCCGTCAAAGGAG     
      
PEPD F: TCCATTCCAAGGAGCACTTCAAGG 544 54 60-45-60 1.5 
cDNA #2 R: AAAGGAGCAGGTGATGTCGG     
      
PEPD F: TGGAAAGCCTCTTCGAGCACTA 1022 54 60-45-60 2.0 
cDNA #3 R: GATTAAAGGTGGGAGCCTGCAAA     
      
CD22 F: AACCCATACACGGAAAGGAAGAAC 472 56 60-45-60 1.5 
Exon 1 R: GGCATCCAATAACCTACCCTACTC     
      
CD22 F: GCCAGAGAAACGCTTGAGC 527 56 60-45-60 1.5 
Exon 2 R: CAGAGATACACAAAGACAGCAGGA     
      
CD22 F: TGGACAACATAGCAAGACC 819 58 60-45-60 1.5 
Exon 3 R: TGGTGAGAAAGAAAGAGGGAAAG     
      
CD22 F: GACTGGAGAGAGGTGGAATGAAG 732 58 60-45-60 1.5 
Exon 4 R: TGAATGAATGAGGCACAAGATAATGATG     
      
CD22 F: AGAAGTAGAGGAAGTGGGAGG 915 58 60-45-60 1.5 
Exons 5-6 R: CATCTGCCTTCCCCGTTC     
      
CD22 F: GCACCAAACCACAGCCAG 1086 58 60-45-60 1.5 
Exons 7-8 R: GCACTCTTCCCCTCCATCAC     
      
CD22 F: GCTGGGATGAGGGGATGAAG 1110 58 60-45-60 1.5 
Exons 8-9 R: AGGCTGAGGCGAAAGGATTG     
      
CD22 F: CCGTTGTCACCCTCTTCCTC 558 58 60-45-60 1.5 
Exons 10-
11 
R: ATGTTGGCTACGCTGGTCTC     
      
CD22 F: GGGAAACAAGGTGAAGGAAGG 372 56 60-45-60 1.5 
Exon 12 R: GAGTGGGAATGAGGCAGAG     
      
CD22 F: CATAAGGGGCTGAAGTTGG 866 58 60-45-60 1.5 
Exon 13 R: GAGTTTTGGAGGTTTGGGGTTAC     
      
CD22 F: GGGTGGAATGAAGGAGAGAATG 564 54 60-45-60 1.5 
Exon 14 #1 R: CAGGAGGGACACAAGCAG     
      
CD22 F: GTTCTCTTCCACTCTCCTTGCTAC 537 56 60-45-60 1.5 
Exon 14 #2 R: CACTGTGACTCCATTTCCTTCC     
Abbreviations: bp, base pairs 
  
79 
Table 7. Sequencing primers used for CEBPG, PEPD and CD22. 
PCR Reaction Primer Sequence Tm (°C) 
CEPBG F1: CCTGCTCTCATTTCTACCTGTTCT 56.3 
Coding F2: CAACGCCGAGAGAGGAACAA 57.4 
 R1: AGCCATTGACATGAGTGGTG 55.3 
 R2: GTGTGTCTTGTGCTTTCTGCT 55.9 
   
PEPD F: GCTGACGCCGCACTTCAC 59.9 
cDNA #1 R: CTGCCGCTGTCCGTGTTG 59.6 
   
PEPD F: TAGATGAGATTGCCAGCGTC 54.5 
cDNA #2 R: CCCATGTCGAACAGGCAC 56.4 
   
PEPD F1: ATGCGCCACAGCTCCTAC 57.9 
cDNA #3 F2: TGGGTGCCATGAAGCCAG 58.3 
 R1: GCCGTCTCTCGCTACTGG 57.8 
 R2: TCCACGCCCTCTGGGTAG 59.1 
   
CD22 F: TCAGAGCCATAGAGAAGCAGG 56.1 
Exon 1 R: GGTAAGAGAGACCAGGGAG 56.4 
   
CD22 F: CATCCCAAATGCCACATCC 54.2 
Exon 2 R: CTGGGTCTTTCCTCCTCCTC 56.3 
   
CD22 F: TGGACAACATAGCAAGACC 52.2 
Exon 3 R: GCCATCGTCATCCGCTG 56.6 
   
CD22 F: GGTGATTTGGGACAGGACA 54.7 
Exon 4 R: GAAACACCAGGGCTGACAAG 56 
   
CD22 F: GCACTTTCCACACCCTCC 56.2 
Exons 5-6 R: CATCTGCCTTCCCCGTTC 56 
   
CD22 F: ACAGGTAGCGGGAGAAGAG 56 
Exons 7-8 R: CACTGGTCCCTTCTCTGCTC 57.4 
   
CD22 F: GGACAGCAAAAGGGACAGG 56.1 
Exons 8-9 R: CAGTGAGGTGTCATTATGCGAC 55.8 
   
CD22 F: AGAAGGACGAGTCTGGCTG 56.5 
Exons 10-11 R: ATGTTGGCTACGCTGGTCTC 57.3 
   
CD22 F: GGTGAAGGAAGGGGATAAAATGTC 55.6 
Exon 12 R: TGGCACAAAGAGGGCAGG 58.2 
   
CD22 F: TGTTGAGAGGGAGGAGAGTTC 55.7 
Exon 13 R: TCATAGTCGCCCTGAGAAAACC 56.7 
   
CD22 F: GGGTGGAATGAAGGAGAGAATG 55.3 
Exon 14 #1 R: CAGGAGGGACACAAGCAG 55.6 
   
CD22 F: CCATCTAAATACCTGCCCTGAC 55.1 
Exon 14 #2 R: AGACTTTCCCCTCTCCTCATC 55.6 
Abbreviations: Tm, Predicted melting point 
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Table 8. Tissue samples of baboon aorta used for microarray analysis. Samples were 
obtained at necropsy and shipped to Wayne State in RNALater solution. Segment number 
refers to approximate anatomic location as described in Figure 4. Quality control measures were 
performed on isolated RNA using a Nanodrop spectrophotometer and Agilent Bioanalyzer. 
Nanodrop Bioanalyzer 
Aorta Age Sex Segment RNA ID 
Conc 
(ng/µl) 260/280 
Conc 
(ng/µl) 28s/18s RIN 
1 25 F 2 MS8951 4402 1.97    
   3 MS8952 4570 1.93    
   4 MS8953      
   5 MS8954 3910 1.85    
   6 MS8955 4850 1.85    
   7 MS8956 5468 1.88    
   8 MS8957      
   9 MS8958 3610 1.78    
   10 MS8959      
   12 MS8961 4562 1.82    
          
2 7 F 4 KP031 4838 1.46 977 1.8 6.4 
   5 KP032 4075 1.96 779 2.2 6.7 
   6 KP033 2345 2.08 536 2.6 6.9 
   7 KP034 2520 2.08 667 2.4 6.8 
   8 KP035 1454 2.08 682 2.3 6.8 
   9 KP036 3494 2.04 641 2.6 7.2 
   10 KP037 4754 1.62 670 1.7 6.5 
   11 KP038 2635 2.07 632 2.7 7 
   12 KP039 402 2.06 678 01 6.7 
          
3 22 M 1 KP053 115 1.92 40 1.8 N/A2 
   2 KP056 4158 1.94 641 1.8 6.3 
   3 KP057 3104 2.06 725 1.9 6.4 
   4 KP058 3133 2.06 730 1.8 N/A2 
   5 KP059 2175 2.07 723 2.5 6.5 
   6 KP060 2079 2.08 494 2.7 6.6 
   7 KP061 1309 2.08 1016 2.4 7.8 
   8 KP062 3120 2.06 587 2.3 6.4 
   9 KP063 1645 2.08 944 2.3 7.8 
   10 KP064 1164 2.08 583 2.4 7.8 
   11 KP065 2061 2.07 1132 2.4 7.4 
   12 KP066 3750 2.02 567 2.0 6.4 
1 Electrophoretic trace did not align with control sample. 
2 Electrophoresis trace was examined manually and was included; Sample did not differ in 
microarray QC. 
Abbreviations: Conc., concentration; RIN, RNA integrity number 
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Table 9. Human tissue samples from non-aneurysmal aortas used in assessing protein 
expression of HOXA4. Samples were obtained at autopsy and either flash frozen for 
preparation of protein homogenates, embedded in OCT media, or fixed in formalin. 
Sample ID1 
Western Blotting IHC (Frozen/FFPE) 
Case 
ID 
Thor Abd Thor Abd 
Age 
(years) 
Race Sex Cause of  
Death 
1 1096 1104   21 W M Overdose 
2 1159 1194   50 B M Overdose 
3 1205 1240 1206/1199 1237/1242 78 W M CA 
4 8001 8006 9000/6000 9003/6007 4 B M Unknown 
5 8013 8021   41 B M Heart Failure 
6 8025 8031 9023/N.A. 9031/N.A. 28 B M CA 
7 8076 8084  N.A./6094 54 W M CA 
8 8056 8062 9052/6065 9058/6074 69 W F Trauma 
9 8086 8094   52 W F CA 
10 8099 8101  N.A./6115 59 W F CA 
11 8105 8110   54 B M GSW 
12 8118 8127   39 W F Unknown 
13 1016 1028   53 W M GSW 
14 1048 1064 1049/N.A. 1065/N.A. 14 B F Suicide 
15 1032 1044  N.A./1038 53 W M Overdose 
16 1124 1140   20 B M GSW 
17 8005 8010 9005/N.A. 9010/N.A. 10 B M GSW 
18 8034 8044  N.A./6051 48 B F Trauma 
19 8132 8137   20 B M Trauma 
20 8139 8143   23 B M GSW 
21 8147 8151   49 B M CA 
22 8163 8169   49 B F Overdose 
23 8174 8182   53 B M CA 
24 8181 8188  N.A./6204 44 W M Overdose 
25 N.A. N.A.  N.A./6183 88 W F Trauma 
1Sample ID is JL number (ie. 1096 is JL1096). 
Abbreviations: GSW, gunshot wound; CA, cardiac arrest; N.A., not available; W, white; B, black; 
Thor, Thoracic; Abd, Abdominal; FFPE, formalin-fixed, paraffin-embedded. 
 
 
Table 10. Human AAA samples used in immunohistochemistry of CD22 and PEPD. 
Samples were obtained as part of elective repair operations and would have been otherwise 
discarded. All patients were Caucasians. 
ID Age (years) Sex 
AAA1 72 M 
AAA2 67 M 
AAA3 87 F 
AAA4 67 M 
AAA5 64 M 
 
  
82 
Table 11. Primary antibodies used in western blots and immunohistochemical staining. 
Antibodies were selected on criteria of literature evidence when possible, predicted epitope 
specificity, and manufacturer recommended applications. 
Target Antibody Manufacturer Species WB 
Dilution 
WB Load 
(µg protein) 
IHC Dilution 
HOXA4 ab26097 Abcam Rabbit polyclonal 1:2000 20 1:100-1:131 
ACTB A1978 Sigma Mouse monoclonal 1:10,000 20 N/A 
ACTA2 ab5694 Abcam Rabbit polyclonal 1:5000 0.5 N/A 
PEPD 12218-1-AP Proteintech 
Group, Inc. 
Rabbit polyclonal N.A. N.A. 1:75 
CD22 ab953 Abcam Mouse monoclonal N.A. N.A. 1:100 
Abbreviations: WB, western blot; IHC, immunohistochemical staining 
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Table 12. Functional positional candidate genes studied by genetic association. Ten 
genes were identified within the AAA linkage intervals on chromosomes 4 and 19 with 
annotated GO or KEGG functions relevant to AAA. mRNA expression levels for each gene in 
both AAA and control abdominal aortic tissue, as well as a score indicating the differences in 
expression levels (Diff score), were obtained from previous work by the laboratory48. 
Gene Symbol Chr GO Category KEGG Pathway # of 
SNPs 
AAA 
Exp 
Cont 
Exp 
Diff 
Score1 
Peptidase D PEPD 19 N.A. N.A. 25 1299.7 956.6 10.52 
CCAAT-enhancer 
binding protein G 
CEBPG 19 immune 
response; 
others 
N.A. 2 222.0 251.5 -3.27 
CCAAT-enhancer 
binding protein A 
CEBPA 19 myeloid cell 
differentiation 
N.A. 16 630.2 118.0 31.32* 
Glucose phosphate 
isomerase 
GPI 19 humoral 
immune 
response 
N.A. 5 1135.9 758.5 11.57 
Hepcidin 
antimicrobial 
peptide 
HAMP 19 immune 
response; 
others 
N.A. 1 135.7 N.D. 13.57 
CD22 molecule CD22 19 immune 
response; 
others 
B cell receptor 
signaling pathway 
4 578.1 N.D. 16.17 
Nuclear factor of 
kappa light 
polypeptide gene 
enhancer in B-cells 
inhibitor, delta 
NFKBID 19 inflammatory 
response 
N.A. 12 22.4 N.D. 23.80* 
TYRO protein 
tyrosine kinase 
binding protein 
TYROBP 19 cellular 
defense 
response 
natural killer cell 
mediated 
cytotoxicity 
12 4973.0 801.2 41.15* 
Hematopoietic cell 
signal transducer 
HCST 19 N.A. natural killer cell 
mediated 
cytotoxicity 
02 736.4 147.7 33.44* 
Interleukin 15 IL15 4 immune 
response; 
others 
cytokine-cytokine 
receptor 
interaction 
11 141.1 136.7 0.62 
1The Diff Score is generated using a custom algorithm from Illumina. A Diff Score of 13 
corresponds to an approximate p value of 0.05. Genes marked with an asterix (*) were 
significantly different between AAA and control tissues after correction for multiple testing (FDR 
< 0.05). 
2 HCST, TYROBP, and NFKBID are adjacent in the genome. Although no SNPs were 
genotyped in HCST, the two SNPs selected were chosen to represent the major haplotype 
blocks in that genomic region. Similarly, CEPBG and PEPD are adjacent in the genome. 
Abbreviations: Chr, chromosome; N.A., not applicable; N.D., not detected; Exp, Expression; 
Cont, Control 
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Table 13. Results of candidate gene association for SNPs in or around candidate genes 
with nominal p < 0.05. Tests for allelic and genotypic association were carried out by a χ2 test 
and logistic regression, respectively for each SNP. P-values < 0.05 are shown in bold. For 
logistic regression, SNPs with LRT and Wald test p-values < 0.05 were considered nominally 
associated. 
χ2 p-value SNP Gene 
Combined Canadian Belgian 
LRT  
p-value 
Wald  
p-value 
rs756796 CD22 0.020 0.1179 0.0680 0.017 0.016 
rs2267574 CD22 0.011 0.0047 0.4185 0.019 0.016 
rs889140* PEPD 0.0043 0.0248 0.0513 0.0025 0.002 
rs7248389* PEPD 0.0009 0.0220 0.0084 0.001 0.0008 
rs7250833 PEPD 0.032 0.1582 0.0987 0.043 0.042 
rs2241380 PEPD 0.018 0.0831 0.1536 0.035 0.034 
rs11880064 PEPD 0.037 0.1045 0.2124 0.059 0.058 
rs580391 GPI 0.052 0.1143 0.4012 0.040 0.038 
rs7251432 HAMP 0.036 0.0296 0.5193 0.051 0.050 
*SNP was out of Hardy-Weinberg equilibrium in Belgian controls 
Abbreviations: LRT, likelihood ratio test 
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Table 14. Sequence changes detected by cDNA sequencing of PEPD. 
 Chr. Pos. 
(Build 37)1 
Gene 
Feature 
Allele 
Change 
rs/hCV 
Number 
MAF 
(Caucasian)1 
mRNA 
Pos 
AA Residue 
Change1 
1 33,953,912 Exon 9 T->C rs3745969 0.063 (N.D.) 793 220 Y->Y 
2 33,902,652 Exon 11 T->C rs74988985 0.021 (N.D.) 877 248 G->G 
3 33,882,255 Exon 13 C->T  0.021  1231 366 H->H 
4 33,882,222 Exon 13 C->T rs17569 0.104 (0.155) 1264 377 H->H 
5 33,878,845 Exon 14 G->A  0.021 1427 432 A->T 
6 33,878,837 Exon 14 C->T rs17570 0.229 (0.246) 1436 435 L->F 
7 33,878,340 Exon 15 G->T  0.021 1525 464 L->L 
1Chromosomal position and minor allele frequency obtained from the National Center for 
Biotechnology Information (NCBI). Caucasian refers to MAF in the HapMap CEU or other 
Caucasian population available at the NCBI website. Single letter amino acids codes are used 
in Residue Change column. 
Abbreviations: Chr. Pos., Chromosomal position; rs/hCV, RefSeq, human Craig Venter; MAF, 
minor allele frequency; AA, amino acid. 
 
Table 15. PEPD sequence changes by sample number.  
 Sequence Change1 
Sample1 1 2 3 4 5 6 7 
30 T/T T/T C/T C/C G/G C/T G/G 
31 T/T T/T C/C C/C G/G C/C G/G 
32 T/T T/T C/C C/C G/G C/T G/G 
33 T/T T/T C/C C/C G/G C/C G/G 
34 T/T T/T C/C C/T G/G C/C G/G 
35 T/C T/T C/C C/C G/G C/C G/G 
36 T/T T/T C/C C/C G/G T/T G/G 
37 T/C T/T C/C C/C G/G C/C G/G 
38 T/T T/T C/C C/C G/G C/T G/G 
39 T/T T/T C/C C/C G/G C/C G/G 
40 T/T T/T C/C C/C G/G T/T G/G 
41 T/T T/T C/C C/T G/G C/C G/G 
42 T/T T/T C/C C/T G/G C/C G/G 
43 T/T T/T C/C C/T G/G C/T G/G 
44 T/T T/T C/C C/C G/G C/C G/G 
45 T/T T/T C/C C/C G/G C/T G/G 
46 T/T T/T C/C C/C G/G C/C G/T 
47 T/T T/T C/C C/C G/G C/C G/G 
48 T/T T/T C/C C/C G/G C/T G/G 
49 T/C T/C C/C C/C G/G C/C G/G 
50 T/T T/T C/C C/C G/G C/T G/G 
51 T/T T/T C/C C/T G/A C/C G/G 
52 T/T T/T C/C C/C G/G C/C G/G 
53 T/T T/T C/C C/C G/G C/C G/G 
1Sequence Change indicates the genotype at the corresponding position from table 14 for each 
individual whose DNA was sequenced. Sample number refers to samples described in Table 5
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Table 16. Sequence changes identified by CD22 exon sequencing. 
 Chr. Pos. 
(Build 37) 
Gene 
Feature 
Allele 
Change 
rs/hCV Number MAF 
(Caucasian) 
mRNA 
Pos 
AA Residue 
Change 
1 35,823,999 Intron 3 C->T rs881456 0.021 (0.000)    
2 35,824,019 Intron 3 C->G rs10419538 0.104 (0.181)    
3 35,829,381 Intron 6 A->G* rs7248108 0.042 (0.042)    
4 35,831,986 Exon 7 C->T rs25677 0.042 (0.000) 1529 484 C->C 
5 35,832,381 Exon 8 G->A  0.021 1721 548 R->K 
6 35,832,886 Intron 9 T->A  0.021    
7 35,835,940 Intron 10 C->T rs45453699 0.313 (N.D.)    
8 35,836,512 Exon 12 A->G  0.021 2293 739 R->G 
9 35,836,530 Exon 12 G->A rs10406069 0.104 (0.292) 2311 745 G->D 
10 35,836,600 Exon 12 C->A rs34826052 0.042 (N.D.) 2381 768 P->P 
11 35,837,148 Intron 13 G->A hCV25603572 0.021 (0.05)    
12 35,837,150 Intron 13 C->T  0.021    
13 35,837,327 Intron 13 C->T rs58156121 0.063 (N.D.)    
14 35,837,428 Intron 13 G->A rs12985354 0.208 (0.383)    
15 35,837,694 3’ UTR C->T rs73031792 0.250 (N.D.) 2715   
16 35,837,705 3’ UTR A->G rs35529786 0.167 (N.D.) 2726   
17 35,837,724-5 3’ UTR GC I/D1 rs34472317 0.042 (N.D.) 2745-6   
18 35,837,813 3’ UTR C->T  0.042 2834   
19 35,837,846 3’ UTR C->T rs16970255 0.042 (0.000) 2867   
20 35,838,076 3’ UTR C->T rs3088063 0.042 (0.055) 3097   
1Variant allele is GC insertion 
For definitions, see footnote to Table 14. 
 
Table 17. CD22 sequence changes by sample number. 
 Sequence Change2 
Sample2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 171 18 19 20 
1 C/C C/C A/G C/C G/G T/T C/T A/A G/G C/A G/G C/C C/T G/G C/T A/A -/- C/T C/C C/C 
2 C/C C/C A/A C/C G/A T/T C/T A/A G/G C/C G/G C/C C/C G/G C/C A/A -/- C/C C/C C/T 
3 C/C C/G A/A C/C G/G T/T C/C A/A G/A C/C G/A C/C C/C G/A C/C A/G -/+ C/C C/T C/C 
4 C/C C/C A/A C/C G/G T/T C/T A/G G/G C/C G/G C/C C/C G/G C/T A/A -/- C/C C/C C/C 
6 C/C C/C A/A C/C G/G T/T C/T A/A G/G C/C G/G C/C C/C G/A C/T A/A -/- C/C C/C C/C 
7 C/C C/C A/A C/C G/G T/T C/T A/A G/G C/C G/G C/C C/C G/G C/C A/A -/- C/C C/C C/C 
8 C/C C/G A/A C/C G/G T/T T/T A/A G/G C/C G/G C/C C/C G/G C/C A/A -/- C/C C/C C/C 
9 C/C C/C A/A C/C G/G T/T C/C A/A G/A C/C G/G C/C C/C G/A C/C A/G -/- C/C C/C C/C 
10 C/C C/C A/A C/C G/G T/T C/T A/A G/G C/C G/G C/C C/C G/G C/T A/A -/- C/C C/C C/C 
11 C/C C/G A/A C/C G/G T/T C/C A/A G/A C/C G/G C/C C/C G/A C/C A/G -/- C/C C/C C/C 
12 C/C C/C A/A  G/G T/A C/C A/A G/A C/C G/G C/C C/C G/A C/C A/G -/- C/C C/C C/C 
13 C/C C/C A/A C/C G/G T/T C/T A/A G/G C/C G/G C/C C/C G/G C/T A/A -/- C/C C/C C/C 
14 C/T C/C A/A C/C G/G T/T C/C A/A G/G C/C G/G C/C C/C G/G C/C A/G -/- C/C C/C C/C 
17 C/C C/C A/A C/C G/G T/T C/T A/A G/G C/C G/G C/C C/C G/G C/T A/A -/- C/C C/C C/C 
18 C/C C/C A/A C/C G/G T/T C/T A/A G/G C/C G/G C/T C/T G/A C/C A/G -/- C/C C/C C/C 
19 C/C C/C A/A C/C G/G T/T C/T A/A G/G C/C G/G C/C C/C G/A T/T A/A -/- C/C C/C C/C 
20 C/C C/C A/A C/C G/G T/T C/C A/A G/G C/C G/G C/C C/C G/G C/C A/A -/- C/C C/C C/C 
21 C/C C/C A/A C/T G/G T/T C/C A/A G/G C/C G/G C/C C/C G/G C/C A/A -/- C/C C/C C/C 
22 C/C G/G A/A C/C G/G T/T C/T A/A G/A C/C G/G C/C C/C G/A C/T A/G -/- C/C C/C C/C 
23 C/C C/C A/A C/C G/G T/T C/C A/A G/G C/C G/G C/C C/C G/G C/C A/A -/- C/C C/C C/T 
24 C/C C/C A/G C/T G/G T/T C/C A/A G/G C/A G/G C/C C/T G/G C/C A/A -/+ C/T C/T C/C 
25 C/C C/C A/A C/C G/G T/T T/T A/A G/G C/C G/G C/C C/C G/G C/T A/A -/- C/C C/C C/C 
26        A/A G/G C/C           
27 C/C C/C A/A C/C G/G T/T C/C A/A G/G C/C G/G C/C C/C G/A C/T A/A -/- C/C C/C C/C 
28 C/C C/C A/A C/C G/G T/T C/C    G/G C/C C/C G/A C/T A/G -/- C/C C/C C/C 
29    C/C                 
1 -/+ = deletion/GC insertion 
2Genotypes at the corresponding position from table 16 for each individual whose DNA was 
sequenced as described in Table 4. 
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Table 18. Genes identified by linear regression analysis of baboon microarray data. 
Linear regression analysis was conducted for segment number versus expression on each gene 
probed by the Sentrix WG-6 and HumanRef-8 microarray platforms. Regression line slopes and 
99% CIs are shown for each gene with a slope different from zero in both platforms. 
Sentrix WG-6 HumanRef-8 
99% C.I 99% C.I 
Gene ID Gene 
Symbol Slope 
Lower Upper 
Slope 
Lower Upper 
133 ADM 10.1 3.6 16.6 6.0 1.2 10.8 
419 ART3 26.9 4.5 49.3 199.3 18.4 380.1 
1031 CDKN2C -14.5 -26.3 -2.7 -28.1 -53.8 -2.3 
1687 DFNA5 -36.5 -48.0 -25.0 -264.7 -513.1 -16.3 
3199 HOXA2 -15.8 -21.1 -10.6 -69.7 -118.0 -21.3 
3205 HOXA9 22.7 7.8 37.6 212.8 70.1 355.5 
3223 HOXC6 70.5 33.2 107.9 418.3 30.9 805.8 
6647 SOD1 -34.5 -59.0 -10.1 -263.9 -524.6 -3.1 
7025 NR2F1 24.5 8.2 40.8 82.3 9.0 155.7 
7035 TFPI 6.9 1.7 12.1 41.3 5.3 77.2 
7045 TGFBI 68.2 34.7 101.8 364.7 61.0 668.4 
8428 STK24 40.2 3.2 77.1 216.1 30.2 401.9 
10397 NDRG1 72.8 4.8 140.8 266.1 66.0 466.3 
10409 BASP1 74.3 5.6 143.1 281.4 60.7 502.2 
25807 RHBDD3 -14.1 -22.2 -6.0 -56.3 -94.5 -18.0 
56994 CHPT1 -21.2 -34.4 -8.0 -97.0 -166.76 -27.23 
83543 AIF1L 180.1 33.5 326.8 1050.8 177.4 1924.2 
83716 CRISPLD2 30.6 14.7 46.6 148.2 0.2 296.2 
84518 CNFN -25.1 -49.3 -0.8 -86.1 -158.8 -13.3 
93664 CADPS2 -5.6 -11.0 -0.3 -82.3 -147.4 -17.1 
126823 KLHDC9 -8.4 -14.1 -2.8 -17.3 -33.2 -1.5 
138046 RALYL 9.1 0.3 17.9 66.4 13.1 119.6 
154791 C7orf55 -37.2 -55.5 -18.9 -46.5 -92.7 -0.3 
Abbreviations: 99% CI, 99 percent confidence interval. 
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Appendix B – Figures 
Figure 1. Sites of aneurysmal disease in the aorta. Several regions of the aorta are prone to 
aneurysm formation, including the ascending aorta, proximal descending aorta and infrarenal 
abdominal aorta. The abdominal aorta is the most common site, with a prevalence of 
aneurysmal disease six times greater than the thoracic aorta. Image courtesy of Marc Nischan 
and reproduced with permission from Nischan, et al., 2010318. 
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Figure 2. Gross appearance of an AAA. Image of an 5.5 cm unruptured AAA in a 74-year-old 
Japanese male obtained during elective open surgical repair. Image courtesy of Yoshiki Kyo, 
M.D. from the Department of Cardiovascular Surgery, Higashihirosima Medical Center, 
Hiroshima, Japan. Reproduced with permission from Nischan, et al., 2010318. 
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Figure 3. Images of PCR product bands used in candidate gene sequencing. PCR 
products for CEPBG (A), PEPD (B) and CD22 (C) (see Table 5 for primer information) were 
electrophoresed in agarose gels (variable concentration) and stained with ethidium bromide. 
100 bp ladder marker (D) or Lambda DNA-BstE II Digest (E) from New England Biolabs 
(Ipswich, MA) were used to assess product molecular weight depending upon predicted product 
size. 
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Figure 4. Diagram of section numbering used for baboon aortas. Anatomical landmarks, 
including the aortic arch (section 1), renal arteries (section 8) and iliac bifurcation (section 12), 
were used for segment numbering to allow for cross-comparison of baboon aortas during 
microarray analysis. 
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Figure 5. Dissection of baboon aortic tissue. Images showing RNALater-treated aortic 
sample (A). Samples were stripped of the gross adventitial fibrous tissue, minced, with a scalpel 
(B) and used for RNA isolation. 
 A 
 
 B 
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Figure 6. Principle components analysis (PCA) of microarray signal data. PCA was 
performed on normalized signal from the Sentrix WG6 (A) and HumanRef8 data (B) in order to 
determine the presence of any outlier samples. No samples were considered significant outliers 
or excluded by PCA. In the HumanRef8 arrays, samples tended to group by animal of origin. (B 
= baboon; S = Segment; i.e. B1.S1 – Baboon1.Segment 1) 
A 
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Figure 6 Cont. 
B 
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Figure 7. Representative SDS-PAGE gel of protein homogenates used in western 
blotting. 7.5 µg of protein was loaded on gels, electrophoresed, and stained using a Rapid 
Coomassie protocol. No evidence of significant protein degradation was observed in any of the 
48 samples used in western blotting. Samples used in western blotting are labeled at top. Other 
lanes are aortic tissue not analyzed by western blot. Protein marker (Novex® Sharp Prestained 
Protein Standard, Invitrogen Corporation, Carlsbad, CA) is on shown on the right with band 
sizes indicated in kDa. 
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Figure 8. Linkage disequilibrium (LD) plot of genotyped SNPs in CEBPG and PEPD. 
Genotype frequency data for each SNP genotyped in the region of CEBPG and PEPD were 
downloaded from the HapMap project and input into Haploview software. The LD plot was 
constructed using r2 as the LD statistic, with black indicating 100% LD and white indicating no 
LD. SNPs marked with an asterix (*) were nominally associated with AAA. 
A 
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Figure 9. LD plot of validated SNPs from the HapMap project in the region of CD22. LD 
plot was constructed in a manner similar to that described for Figure 8. SNPs indicated in red 
were genotyped and SNPs indicated in blue are appropriate for further study based on the 
criterion of a MAF of > 0.05. 
B 
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Figure 10. Immunohistochemistry of CD22 and PEPD demonstrates expression in aortic 
tissue. Immunohistochemical staining using antibodies against CD22 (A) or PEPD (B) was 
performed on formalin-fixed paraffin embedded tissue sections of abdominal aorta and AAA and 
either tonsil or kidney as positive controls. Negative control staining with non-immune serum 
showed no cross-reactivity of the primary antibodies (data not shown). Regions of positive 
staining appear reddish-brown (indicated by black arrows) with hematoxylin counterstaining in 
blue. 
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Figure 10 cont. 
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Figure 11. Sequence variants identified by candidate gene sequencing. Variants in PEPD 
(A) and CD22 (B) plotted to show their relative chromosomal positions and positions relative to 
gene features. 
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Figure 12: Predicted effects of A432T and L435F amino acid substitutions on the 
structure of PEPD. Model structures were generated using Swiss-Model Software (Template 
2iw2A.pdb). Superimposed structural differences of wild-type (colored) and mutant (white) 
amino acids are shown in full protein (A) and detailed (B) views. 
A 
 
B 
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Figure 13. Predicted miRNA binding sites in the 3’ UTR of CD22 that overlap sequence 
variants identified by DNA sequencing. Predicted miRNA binding sites were identified using 
the MirBase Targets database234,235. The sequence variants rs73031792 (A) and rs16970255 
(B), indicated in black, were located in the predicted binding sites of miRNAs shown. 
 
A 
hsa-miR-933 
CUCCAGAGGGACGCGUGU 
|:  || :|||||||:|| 
GGCTTCCTCCTGCGCGCA 
 
hsa-miR-560 
CCGCCGGCCGGC-CGCGUGCG 
|||  ||  |:| |||||:|: 
GGCTTCCTCCTGCGCGCATGT 
 
B 
hsa-miR-490-5p 
GGUGGACCUCUAGGUA  
|:|||  || |||||| 
CTACCCAGAAATCCAT 
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Figure 14. Spatial expression changes in HOX genes in baboon aortic tissue. Log2 
transformed expression data HOX genes detected in baboon aortas using both microarray 
platforms (A), HumanRef8 only (B) or Sentrix WG6 only (C). Expression is plotted against aortic 
segment (as described in Figure 4). Sentrix WG6 (Red) and HumanRef8 (Blue) data are plotted 
on different Y-axis scales to allow for comparison of expression pattern. Genes in bold had 
statistically significant expression patterns by linear regression. 
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Figure 14 cont. 
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Figure 15. HOX gene transcripts are significantly decreased in AAA tissue compared with 
controls. Box-and-whiskers plot of gene expression data of HOX genes with significantly 
different expression between AAA (n = 7) and abdominal aortic control (n = 7) tissue. HOXA4 
(second from left) was the most significantly differentially expressed HOX gene. 
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Figure 16. Immunohistochemical staining shows HOXA4 protein in aortic tissue. A: 
Immunohistochemical staining (reddish-brown) of both frozen and FFPE thoracic aortic sections 
showing evidence of HOXA4 in all three histological layers. B: High-power objective (40X) 
images showing staining were primarily present in the nuclei of ECs and SMCs (Black arrows). 
C: Thoracic aorta of a 78 y.o. (40X) showing aggregate-like staining artifact present in several 
sections. D-E: Tissue localization of staining did not appear to differ between thoracic and 
abdominal aorta. Although there was a visible trend towards increased thoracic staining, 
quantification was not performed due to the aggregate-like staining. 
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Figure 16 cont. 
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Figure 16 cont. 
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Figure 17. Aortic tissue sections from adolescent and adult donors exhibit different 
staining patterns. Immunohistochemical staining of both frozen (A) and FFPE (B) tissue 
sections exhibited primarily nuclear and perinuclear staining in sections from adolescent donors 
(black arrows). Nuclear staining was observed in tissue from adult donors but most staining was 
the intense aggregate-like staining deemed to likely be nonspecific (white arrows). 
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Figure 17, cont. 
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Figure 18. Protein bands observed by western blot analysis. Representative western blots 
lanes using antibodies directed against HOXA4 (A, B), ACTA2 (C), and ACTB (D). 
Chemiluminescence and epi-luminescent exposures of the blots were obtained sequentially and 
overlaid to visualize bands and molecular weight markers, respectively. Relevant marker band 
sizes are labeled to the left of images. Protein bands were observed at the expected molecular 
weights of ~33 kDa (A), ~42 kDa (C), and ~42 kDa (D). Reactivity against the immunizing 
peptide (ab32311, Abcam Inc., Cambridge, MA) was assessed with the HOXA4 antibody (B). 
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Figure 19. Western blots of HOXA4, ACTA2, and ACTB on paired thoracic and abdominal 
aortic tissue samples. Bands for each protein from all 48 samples used for quantification of 
HOXA4 are shown. Sample refers to sample number described in table 9. Note: HOXA4 bands 
for sample five and ACTA2 bands for samples 1-4 and 5-8 were loaded out of order and have 
been rearranged for this figure. T = Thoracic, A = Abdominal. 
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Figure 20. HOXA4 protein levels are significantly in decreased in abdominal aorta 
compared to thoracic aorta. HOXA4 band intensity was quantified using BioRad Quantity One 
Software and adjusted for band beta-actin (A) and smooth muscle alpha actin expression (B). 
Boxes represent 25-75 percentiles and whiskers represent 1.5 times the interquartile range. 
Expression between thoracic and abdominal tissues was compared using a Wilcoxon signed 
rank test as the test statistic. * = p < 0.0001, ** = p < 0.001. 
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Figure 21. HOXA4 shows decreasing expression with age. Regression lines were calculated 
using beta-actin adjusted HOXA4 protein levels for age versus either thoracic or abdominal 
protein expression. Slopes were significantly different from zero for both aortic locations 
(Thoracic: slope = -0.95 (99% C.I. -1.66, -0.24); R2 = 0.43; F-statistic p =. 0.0005. Abdominal: 
slope = -0.58 (99% C.I. -1.02, -0.13); R2 = 0.41; F-statistic p = 0.00075). 
 
  
115 
Figure 22. HOXA4 localizes to the perinuclear region in vascular cells. Cultured primary 
HAECs (A,B), (PromoCell, ScienCell Research Laboratories) and HASMCs (C,D) (ScienCell, 
ATCC) were used for immunofluorescent staining. Staining with anti-HOXA4 antibody and a 
fluorescein conjugated secondary revealed HOXA4 is shown in green. Cell structure was 
visualized in red using rhodamine-phalloidin to stain filamentous actin. Nuclei were visualized in 
blue using DAPI. 
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 Abdominal aortic aneurysm (AAA) is a common disease for which mechanisms of 
formation are still not well understood. Despite a strong genetic component to AAA risk, specific 
risk alleles are still largely unidentified. AAA is also a localized disease with a majority occurring 
in the infrarenal abdominal aorta and is six times more common than aneurysms of the thoracic 
aorta. To determine whether risk alleles are present in functional positional candidate genes. 
we: 1. performed a genetic association study using DNA from AAA cases and controls in ten 
candidate genes and 2. performed exon sequencing on three genes with evidence of nominal 
association. To identify genes with regional expression in the aorta of potential relevance to 
AAA: 1. Illumina microarrays were used to perform a gene expression profiling of entire baboon 
aortas and 2. protein expression of one candidate gene, HOXA4, was examined in further detail. 
 Single nucleotide polymorphisms in three positional candidate genes, CEBPG, PEPD 
and CD22, that had both functions relevant to AAA and expression in AAA tissue exhibited 
nominal association and further studied by DNA sequencing of exons. Sequence variants were 
identified in PEPD and CD22, but not CEPBG, but no sequence variants had predicted 
functional changes. Analysis of the gene expression profiles from whole length baboon aortas 
identified 26 genes that exhibited lengthwise expression changes along aorta, including three 
genes from the homeobox (HOX) family of transcription factors. Comparison of HOX gene 
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transcripts between AAA and control abdominal aortic tissue identified ten HOX genes that were 
significantly downregulated in AAA tissue. The most significantly downregulated HOX gene, 
HOXA4, also exhibited spatial expression changes and was studied in human aortic tissue. 
Immunohistochemical staining of sections of human aorta using an antibody directed against 
HOXA4 showed expression in all three histological layers of the aorta, primarily by endothelial 
cells and smooth muscle cells. Immunohistochemical analysis and immunofluorescent staining 
of cultured cells in vitro demonstrated protein expression localizing to the nucleus and 
perinuclear regions of endothelial and smooth muscle cells. Quantitative analysis of HOXA4 
protein by western blot in 24 paired human thoracic and abdominal aortic samples showed that, 
consistent with the microarray results, HOXA4 had significantly lower expression (p < 0.0001) in 
the abdominal aorta. A negative correlation was also shown between HOXA4 was 
demonstrated between HOXA4 protein levels and increasing in both thoracic and abdominal 
aorta. 
 In conclusion, several novel genes with potential roles in AAA etiology and pathogenesis 
have been identified using two different methods. Two plausible functional candidate genes 
from a region with evidence of genetic linkage, CD22 and PEPD, were shown to have evidence 
of nominal association, suggesting that variation in or around these genes may contribute to the 
risk of developing an AAA. HOXA4 is a novel candidate gene with differential expression by 
aortic location and age. Lower levels of HOXA4 in the abdominal aorta and further decreases in 
expression with increasing age suggest that HOXA4 may have a protective function with respect 
to AAA. 
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